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Sensory stimuli are detected by primary sensory neurons whose cell bodies reside in 
the dorsal root ganglia (DRG) of the peripheral nervous system (PNS). In the DRG， 
glial cells, including satellite glial cells (SGCs) and Schwann cells, are closely 
associated with the primary sensory neurons. The primary functions of glial cells are 
to regulate the trafficking of extracellular ions and neurotransmitters for proper 
neuronal function and survival. In the early study of pain, DRG were examined and 
sensory neurons were presumed to be the sole players leading to the development of 
pain while the associated glial cells were thought not to be directly involved. 
Recently, however, glial cells have emerged as important contributors to the 
maintenance and amplification of pain by bidirectional neuron-glia interactions.' 
i 
In isolated DRG cell cultures, neurons and glial cells in a mixed cell population can 
be enriched and studied separately. We have recently characterized the functional 
expression of pain-related prostanoid receptors (EP4 and IP receptors) in isolated 
cultures of DRG neurons and glial cells using pharmacological methods. Besides, the 
prostanoid receptor agonist-stimulated responses in glial cells were curiously 
inhibited by co-culture with neurons revealing a novel neuron-glia interaction. To 
investigate the effect of neurons on glial cells in isolated cultures, the phenotypic 
properties of different glial cell subtypes were first studied. Antibodies against glial 
fibrillary acidic protein (GFAP) identified two major types of glial cells, one 
population had a round nucleus with spreading cytoplasm, and the other population 
was bipolar or multipolar and spindle shaped with an elongated nucleus. When DRG 
cells were cultured over time, glial cells proliferated and the number of GFAP-
immunoreactive glial cells increased. These characteristics have also been reported in 
neuropathic pain conditions in vivo which may suggest that isolated glial cells 
behaved similarly to those glial cells in neuropathic pain models. The identification 
of glial cell subtypes and fibroblasts using glial cell-specific antibodies was 
inconclusive and adaptation of other immunocytochemical methods did not facilitate 
their identification. 
The second part of the study was to characterize the expression of other pain-related 
ii 
Gs- and Gj/o-coupled G-protein coupled receptors (GPCRs) on neurons and glial cells, 
and to investigate if the receptor-specific activities of glial cells were also inhibited 
by co-culture with neurons. Results revealed the presence of P2-adrenoceptors (P2-
ARs) and calcitonin gene-related peptide (CGRP) receptors, but not pi-adrenoceptors 
(Pi-ARs), on neurons and glial cells. Consistent with the EP4 and IP receptor agonist-
stimulated responses, the CGRP-stimulated responses in mixed DRG cells were 
smaller than those in the glial cells. This inhibitory pattern was not seen with P2-AR 
agonist stimulation. Characterization of Gj/o-coupled GPCRs was prevented due to 
the failure of Gj/�agonists o inhibit forskolin-stimulated responses. With all agonist 
and forskolin stimulations, neuron-enriched cells produced smaller responses than 
mixed DRG cells and glial cells. Addition of nerve growth factor (NGF) did not 
enhance neuronal responses, despite facilitating neurite outgrowth of neurons. With 
strong evidence that the Gi/o-coupled GPCR should be expressed on DRG cells, other 
methods need to be identified in order to characterize the presence of these receptors 
in DRG neurons and glial cells. 
In conclusion, this thesis suggested that DRG glial cells in isolated cultures may 
mimic neuropathic pain conditions after nerve injury in vivo, and revealed the 
necessity to consider the roles played by the associated glial cells and the neuron-glia 
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1.1 Dorsal root ganglion cells 
1.1.1 Primary sensory neurons 
The dorsal root ganglia (DRG) are located in the intervertebral spaces in the 
peripheral nervous system (PNS) adjacent to the spinal cord (Tang et al, 2007), and 
they consist of neurons and non-neuronal cells (Hanani, 2005). The neurons in the 
DRG are called primary sensory neurons, which are responsible for converting 
sensory stimuli into sensory signals. The primary sensory neurons are 
pseudounipolar where one process extends to the periphery such as skin, muscle and 
internal organs, while the other central process extends and terminates at the dorsal 
horn of the spinal cord (Hanani, 2005). Upon various sensory stimulations, including 
mechanical, thermal and chemical stimuli, the primary sensory neurons are 
responsible for detecting and conveying sensory information from the periphery, and 
transmitting the information in terms of nerve impulses to the brain for perception of 
these sensations. 
‘ 
The primary sensory neurons are classified based on their anatomical and functional 
characteristics. The large diameter neurons are heavily myelinated and they give rise 
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to Aa and Ap fibers (Julius et al., 2001; Milligan et al, 2009). The myelin sheaths on 
these fibers help maintain the electric current in the axon and facilitate propagation 
of impulses along the fiber from node to node (see Section 1.1.2.2). This feature of 
large diameter neurons leads to the fast-conducting velocity for signal transmission. 
The large diameter neurons consist of low threshold mechanoreceptors at the 
terminal and account for detection of innocuous stimulations such as light touch or 
proprioception (Julius et aL, 2001; Milligan et al； 2009; Zhou et al, 2010). The 
medium diameter neurons are lightly myelinated and give rise to the A5 fibers. Being 
lightly myelinated, nerve impulses cannot be efficiently propagated from node to 
node, and therefore, the transmission velocity of the medium diameter neurons is not 
as fast as that of the large diameter neurons. The medium diameter neurons are 
responsible for transmitting harmful stimuli into nociception, a term to refer to 
perception of pain. Lastly, the smaller diameter neurons are non-myelinated, which 
give rise to the C fibers. They have high threshold for activation and they are 
responsible for transmitting nociceptive signals slowly. The difference in the 
transmission velocities between the A6 and C fibers result in the generation of the 
first pain, mediated by the A6 fiber, being sharp, acute and rapid, and the second pain, 
i 
mediated by the C fiber, being more dull, diffuse and delayed (Julius et al, 2001). 
The small diameter neurons are further divided into peptidergic and non-peptidergic 
2 
neurons. The peptidergic, small-diameter neurons express peptide neurotransmitters 
such as substance P and calcitonin gene-related peptide (CGRP). They are 
characterized by the expression of high affinity tyrosine kinase receptors, TrkA 
receptors, for nerve growth factor (NGF). In contrast, the non-peptidergic, small-
diameter neurons do not express substance P, CGRP and TrkA receptors, but they 
can be identified by the binding of lectins such as Griffonia simplicifolia isolectin B4 
(IB4), and the expression of P2X3 receptors, which are a subtype of ATP-gated ion 
channel (Julius et al., 2001). 
1.1.2 Non-neuronal cells 
In the DRG, other than sensory neurons, there are also non-neuronal cells. The 
predominant non-neuronal cells include satellite glial cells (SGCs), Schwann cells 
and fibroblasts. The glial cells, consisting of SGCs and Schwann cells, have close 
associations with the sensory neurons providing not only passive structural supports, 
but also active contribution during normal and pathological states by interactions 
with neurons. 
1.1.2.1 Satellite glial cells 
The SGCs are a type of glial cell in the PNS that closely enwrap the surface of a 
neuronal cell body (Pannese, 1981). They are precisely described as to surround the 
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cell body and the initial segment of the axon of primary sensory neurons, leaving a 
gap of 20 run between themselves and the neuronal cell surface (Ohara et al, 2009; 
Pannese, 1981; Vit et al., 2006). The complete wrapping of the neuronal cell body 
separates adjacent neurons and forms a discrete neuron-SGC structural unit, which 
consists of a single neuronal cell body and an envelope of the SGCs. However, 
clusters of two or three neuronal cell bodies enclosed by the same SGCs can 
occasionally be found (Hanani, 2005; Pannese, 2010). The neuronal ensheathing 
feature is unique to SGCs and is not found in other types of glial cells in the central 
nervous system (CNS) such as astrocytes (Hanani, 2005). Each neuronal cell body is 
normally surrounded by approximately eight SGCs in rat in vivo while the ratio of 
neurons to SGCs varies in different species (Ledda et al., 2004). The principle 
function of SGCs enveloping neurons is to regulate the external chemical 
microenvironment of neurons by physically preventing excessive access of 
extracellular ions, such as K+, into neurons (Vit et ah, 2006). 
The SGCs are connected among themselves by gap junctions (Ohara et al., 2008) and 
they have been shown to communicate with each other by intracellular Ca^^ waves 
(Suadicani et al, 2010). They also possess mechanisms for the release of cytokines 
and adenosine triphosphate (ATP) for signaling (Suadicani et al., 2010; Takeda et al, 
2009). Besides, the various functions of SGCs can be revealed by the expression of 
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numerous ion channels, transporters and surface receptors including GPCRs, such as 
P2Y4 receptors for ATP. For instance, the SGCs express inwardly rectifying K+ 
channels (Kir 4.1 channels) that are responsible for the uptake of extracellular K+ 
into their cell body and the dissipation of the K+ ions through the Ca^"^-activated K+ 
channels and the gap junction proteins, such as connexins (Vit et al, 2006). 
Providing this function, the SGCs help maintain a low extracellular K+ concentration 
for controlling neuronal resting membrane potential and neuronal excitability (Vit et 
aL, 2006). Besides, the SGCs also possess transporters to take up neurotransmitters 
such as glutamate and gamma aminobutyric acid (GABA) (Jasmin et aL, 2010; 
Schon et al, 1974). For example, in human, SGCs express excitatory amino acid 
transporters 1 (EAATl), which is equivalent to the glutamate aspartate transporter 
(GLAST) in rodent, to transport glutamate into their cell body (Ohara et al., 2009; 
Pannese, 2010). Once in the cytoplasm of SGCs, glutamate will be amidated to 
glutamine by another enzyme glutamine synthetase (GS). Glutamine will then be 
subsequently released to the extracellular space. The glutamine will then be taken up 
by the nearby neurons into the cytoplasm and be converted back to glutamate by the 
enzyme phosphate-activated glutaminase (PAG). The SGCs, in this way, provide 
f 
very important protective roles to neurons by maintaining a low extracellular 
concentration of glutamate to prevent interminable activation of neurons, which 
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might lead to excitotoxicity, a condition when neurons are damaged due to high 
concentrations of excitatory neurotransmitters. It has therefore been accepted that the 
primary function of SGCs is to provide tight regulation on the trafficking of 
extracellular ions and neurotransmitters and thereby to prevent the accumulation of 
any of these substances that could potentially harm neurons. 
It has long been assumed that SGCs are passive and protective, but recently it has 
been suggested that the roles of SGCs were being overlooked and underestimated 
(Ledda et al, 2004). The functions of SGCs are more than being passive and 
protective. There is now a great deal of evidence that SGCs actually play very 
important roles in modulating neuronal activities and the development and the 
maintenance of pain (see Section 1.3). 
1.1.2.2 Schwann cells 
Schwann cells are the other type of glial cells in the DRG. They are classified as 
myelinating Schwann cells and non-myelinating Schwann cells (Campana, 2007). 
The myelinating Schwann cells produce myelin, a lipid rich membrane, and wrap 
their plasma membrane around the axon of the medium and large diameter neurons 
I 
to form a segment of myelin sheath (Campana, 2007). The myelin sheaths are not 
continuous, leaving gaps in between called nodes of Ranvier (Bhatheja et al., 2006). 
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The sheathed regions of the axon membrane are highly insulated, in which only little 
current can leak across it. At the node of Ranvier, voltage-gated Na+ channels are 
highly concentrated and therefore, depolarization of the axon membrane is actively 
confined at the nodes of Ranvier. Thus, action potential generated at one node almost 
immediately spreads to the next node and continues. This allows action potential 
along the axon to jump from node to node, a process called saltatory conduction. 
As a result of saltatory conduction, the speed and the efficiency of action potential 
propagation along a myelinated axon is greatly enhanced when compared with that 
along a non-myelinated axon. The non-myelinating Schwann cells do not produce 
myelin and they ensheath the small diameter neurons (Campana, 2007). The 
functions of non-myelinating Schwann cells are thought to provide supportive roles 
for and communicate with the small diameter neurons for proper neuronal functions 
(Chen et al., 2003). It is suggested that Schwann cells are sensitive to nerve injury by 
modulating their phenotype, proliferation, migration and secretion of pro-
inflammatory cytokines, such as tumor necrosis factor-a (TNF-a), interleukin ip (IL-
IP) and interleukin 6 (IL-6) (Campana, 2007). In addition, the activated Schwann 
cells are also recruited to form a scaffold for regenerating axons to grow along, 
which ultimately lead to the re-innervation of the target and functional recovery of 
the axon following nerve injury (Vroemen et al, 2003). 
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1.2 Peripheral sensitization 
Under normal physiological conditions, pain signals are not generated due to the high 
threshold of nociceptive neurons for activation (Milligan et al., 2009). Nevertheless, 
after nerve injury, primary sensory neurons are subject to the change of their 
plasticity, which refers to the change of neuronal functions and chemical profiles 
(Woolf et al., 2000). These changes alter the normal functions of neurons. For 
example, upon repeated noxious stimulation, nociceptive neurons increase their 
responsiveness by lowering the threshold to generate pain signals. This results in 
increased and more frequent responses than that of a given normal afferent input. 
This situation is often referred as hyperalgesia, a state in which the sensitivity to pain 
is augmented. In other words, pain is elicited by even gentle stimuli when 
hyperalgesia has developed. 
Neuropathic pain refers to a type pathological pain resulting from nerve injuries in 
the PNS (Vit et al., 2008). It leads to hyperalgesia that is resistant to treatment by 
common analgesics. The major factor leading to hyperalgesia is the change of 
plasticity of the DRG neurons from the exclusive detection of noxious stimulus to the 
detection of innocuous stimuli, a process called peripheral sensitization (Woolfer al., 
2007). The development and the maintenance of neuropathic pain not only involves 
primary sensory neurons, but also immune and glial cells (Scholz et al., 2007). 
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Neurons are sensitized through several different pathways. One of the important 
ways is to enhance the production of intracellular cyclic adenosine monophosphate 
(cAMP). In response to physical injury or inflammatory insult, prostanoids are 
released by the injured cells and immune cells (Julius et al, 2001). Among the 
prostanoids released, prostaglandin Ei (PGE2) is one of the key contributors to the 
development of pain. PGE2 binds to EP receptors such as EP4, a GPCR which 
couples with Gs protein and is expressed on primary sensory neurons (Bley et ah, 
1998). This results in the increase of the intracellular level of cAMP at the nociceptor 
by enhancing the activity of adenylate cyclase (Bley et al, 1998). The increase in 
cAMP level activates protein kinase A (PKA) and its downstream pathways, causing 
the phosphorylation of voltage-gated channels, such as the tetrodotoxin-resistant 
(TTX-R) Na+ channel, and the ligand-gated ion channel, TRPVl (Bhave et al.，2002; 
Hucho et al., 2007). For example, phosphorylation of Na+ channels potentiates the 
influx of Na+, depolarizes the nociceptor, and lowers the threshold for generating an 
action potential, which favors repetitive firings of pain signals by nociceptive 
neurons (Julius et al, 2001). 
1.3 Neuron-glia interactions 
The above descriptions of SGCs and Schwann cells demonstrated their essential 
protective roles to DRG neurons (see Sections 1.1.2.1 and 1.1.2.2). The relationship 
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of glial cells to neurons has long been considered as passive. Moreover, it was 
thought that neurons were the only cells that mediated pain sensations because of the 
characteristics to transduce noxious signals. However, it has recently been suggested 
that interactions between neurons and glial cells are bidirectional and glial cells play 
important roles in modulating pain development and processing. The evidence for 
interactions between neurons and glial cells to modulate pain processing includes the 
demonstration that silencing Kir 4.1 channel subunit in SGCs of the rat trigeminal 
ganglion (TG) results in pain-like behavior in the absence of nerve injury (Vit et al., 
2008). Besides, we previously demonstrated that glial cells induced neurite retraction 
of IB4-negative large diameter neurons when Gj/�proteins were inhibited. This 
indicates that glial cells constitutively release factors that influence neurite outgrowth 
(Ng et al, 2010). Moreover, increase in expression of glial cell specific gap junction 
protein subunit, connexin 43 (CX43), was reported in a rat model with chronic 
constriction injury (Ohara et al., 2008). The role of CX43 in pain was revealed by the 
reduced pain-like behavior after down-regulation of CX43 using siRNA (Ohara et al， 
2008). 
Recently we showed that pain-related prostanoid receptors (EP4 and IP receptors) 
were surprisingly expressed on glial cells in vitro, in addition to neurons (Ng et al., 
2011). The majority of prostanoid-stimulated cAMP production was seen in glial 
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cells although production of cAMP in neurons is proposed to facilitate pain. 
Moreover, the presence of neurons inhibited prostanoid-stimulated cAMP production 
in glial cells (see Section 5.1.2). The expression of pain-related receptors on glial 
cells and the inhibitory effect of neurons on glial cell responses suggested that it was 
important to consider the roles played by glial cells and the effect of neuron-glial 
interactions. 
Together with evidence to support bidirectional neuron-glial interactions, it is now 
clear and accepted that the glial cells play very active roles in modulating the 
neuronal activity. The glial cells modulate the process of pain development and 
therefore, the functions of glial cells should not be overlooked. 
1.4 Aim of Thesis 
It is now clear that neurons and glial cells undergo bidirectional interactions to 
influence the activities of each other. Besides, we have recently identified the 
presence of pain-related GPCRs (EP4 and IP receptors) on both DRG neurons and 
glial cells in vitro; it is therefore appropriate to reinterpret the expressions of GPCRs 
that mediate pain on DRG neurons and glial cells. The full understanding of the 
neuron-glia interaction requires the identification of neurons and the types of glial 
cells in isolated DRG cell preparations. 
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The aim of first part of the thesis was to identify different types of glial cells and any 
fibroblasts in isolated DRG cultures with the use of various antibodies specific for 
different non-neuronal cells. Then, in response to our recent finding that shows (1) 
pain-related prostanoid receptors (EP4 and IP receptors) were expressed on both 
neurons and glial cells in cultures of rat DRG and (2) prostanoid receptor agonist-
stimulated responses in glial cells were inhibited by co-culture with neurons, the aim 
of the second part of the thesis was to characterize the expression of other pain-
related Gs- and Gj/o-coupled GPCRs on neurons and glial cells in cultures with the 
use of receptor-specific agonists and antagonists. Besides, we aimed to identify if 
any other receptor-specific activity of glial cells would also be inhibited by co-




Materials, media, buffers and solutions 
2.1 Materials 
[8-^H]adenine (specific activity 29.0 Ci/mmol, stored at 4 Amersham) 
8-hydroxy-DPAT hydrobromide (8-OH-DPAT; Tocris Bioscience) was dissolved in 
ddH20 at 20 mM and aliquots were stored at -20 °C. 
Acetone (Lab Scan) 
Adenosine 5'-triphosphate (ATP; Sigma) 
Alumina column (Aluminum oxide, neutral type WN-3; Sigma) 
AM251 (Tocris Bioscience) was dissolved in absolute ethanol at 20 mM and aliquots 
were stored at -20 
AM630 (Tocris Bioscience) was dissolved in DMSO at 50 mM and aliquots were 
stored at -20 
S-(-)-atenolol (Tocris Bioscience) was dissolved in ddHbO at 25 mM and aliquots 
were stored at -20 
4 
Bovine serum albumin (BSA; Sigma) 
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CGRP (species: rat; Tocris Bioscience) was dissolved in ddHaO at 1 mM and 
aliquots were stored at -20 °C. 
CGRPg-s? (species: rat; Tocris Bioscience) was dissolved in ddHiO at 10 mM and 
aliquots were stored at -20 °C. 
Cicaprost (Gift from Schering AG, Germany) was dissolved in ddHiO at 1 mM and 
aliquots were stored at -20 
Collagenase B (Roche) was prepared as a 1.25% stock in Ham's F14 medium and 
aliquots were stored at -20 °C. 
DAMGO (Tocris Bioscience) was dissolved in ddHzO at 10 mM and aliquots were 
stored at -20 °C. 
Deoxyribonuclease I (DNase I; Sigma) 
Dimethyl sulfoxide (DMSO; Sigma) 
Dorminal (20% pentobarbital solution; Alfasan) was diluted to a 5% solution with 
ddH20 before use. 
Dowex column (AG SOW X4 resin, 200 - 400 mesh hydrogen form; Bio Rad) 
Ethanol (Absolute; Merck) 
14 
Formoterol hemifumarate (Tocris Bioscience) was dissolved in DMSO at 50 mM 
and aliquots were stored at -20 
Forskolin (Sigma) was dissolved in DMSO as a 10 mM stock and aliquots were 
stored at -20 
Glass coverslips (12 mm and 25 mm; Menzel Glaser) 
Glass slide (Marienfeld Laboratory Glassware) 
Glucose (Sigma) 
L-Glutamine (Life Technologies) was prepared as a 200 mM solution in ddHzO, 
filter sterilized, and aliquots were stored at -20 
Glycerol (Sigma) 
HEPES (Sigma) 
Hoechst 33342 (Invitrogen) was prepared as a 10 mg/ml stock in ddHzO，aliquots 
were stored at -20 
Hydrochloric acid (HCl, 12.1 M; Merck) 
IBMX (3-isobutyl-1 -methyl-xanthine; Sigma) was prepared as a 100 mM stock in 
DMSO and aliquots were stored at -20 
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ICI118551 hydrochloride (Tocris Bioscience) was dissolved in DMSO at 10 mM 
and aliquots were stored at -20 
Imidazole hydrochloride (Sigma) 
Isoproterenol hydrochloride (Isoprenaline; Tocris Bioscience) was dissolved in 
ddHzO at 100 mM and aliquots were stored at -20 °C. 
(±)-Jl 13397 (Tocris Bioscience) was dissolved in absolute ethanol at 50 mM and 
aliquots were stored at -20°C. 
L-759656 (Tocris Bioscience) was dissolved in DMSO at 100 mM and aliquots were 
stored at -20�C. 
Laminin (Roche) was prepared as a 0.25 mg/ml stock in sterile PBS and aliquots 
were stored at -20 
R-(+)-methanandamide (Tocris Bioscience) was dissolved in absolute ethanol at 13.8 
mM and aliquots were stored at -20 
Methanol (Lab Scan) 
Naloxone hydrochloride (Tocris Bioscience) was dissolved in ddHaO at 100 mM and 
aliquots were stored at -20 
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Nerve growth factor (NGF mouse 2.5s; Alomone Laboratories) was dissolved in F14 
medium at 10 jig/ml and aliquots were stored at -80 
Nociceptin (N/OFQ; Tocris Bioscience) was dissolved in ddHzO at 10 mM and 
aliquots were stored at -20 
Normal Donkey serum (Jackson Immunoresearch) 
ONO-AE1-329 (Gift from ONO Pharmaceuticals, Japan) was dissolved in ddHaO at 
100 mM and aliquots were stored at -80 
OptiPhase 'Hi-safe'3 (Perkin Elmer) 
Paraformaldehyde (Sigma) 
Penicillin/Streptomycin (10000 units/ml and 10000 |xg/ml; Gibco) was reconstituted 
with 20 ml ddHzO and stored at 4 
Poly-DL-omithine (Sigma) was prepared as a 25 mg/ml stock solution in ddHaO, 
filter sterilized, aliquots were stored at -20 
Polyethylene glycol (PEG; Sigma) 
Prostaglandin E2 (PGE2； Sigma) was dissolved in absolute ethanol at 10 mM and 
4 
aliquots were stored at -20 
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Rauwolscine hydrochloride (yohimbine; Tocris Bioscience) was dissolved in DMSO 
at 20 mM and aliquots were stored at -20 
Soybean trypsin inhibitor (Sigma) 
Trichloroacetic acid (TCA; Sigma) was prepared as a 10% stock (w/v) in ddHaO, 
stored at 4 °C. 
Triton X-100 (Sigma) 
Trypan blue was prepared as a 0.4% stock in PBS, stored at room temperature. 
Trypsin (Sigma) was prepared as a 25 mg/ml stock in sterile PBS, aliquots were 
stored at -20 
Trypsin inhibitor (Type I-S, From Soybean; Sigma) 
UK14304 (Tocris Bioscience) was dissolved in DMSO at 100 mM and aliquots were 
stored at -20 
Ultroser G (USG; Pall Life Science) was reconstituted with 20 ml sterile ddHzO and 
stored at 4 
S-WAY100135 dihydrochloride (Tocris Bioscience) was dissolved in DMSO at 20 
mM and aliquots were stored at -20 
Common laboratory reagents not listed (ACS grade) were purchased from Sigma. 
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All disposable culture plates were purchased from Nunc. 
2.2 Culture media, buffer and solutions 
2.2.1 Culture media 
Ham's Nutrient Mixture F14 (F14 medium; SAFC Biosciences). One packet of 
F14 powder was reconstituted with 1 L ddHzO, and supplemented with 1.176 g 
NaHCOs. The medium was adjusted to pH 7.2 with 1 M HCl and filter sterilized to 
give a final pH 7.4. Penicillin and streptomycin was added to the medium to give a 
final concentration of 100 units/ml and 100 |ig/ml, respectively. Medium was stored 
at 40c. 
Complete F14 medium. 191 ml of F14 medium was supplemented with 8 ml of 
serum substitute USG (4%, v/v) and 1 ml of L-glutamine (1 mM) immediately prior 
to use. 
2.2.2 General culture buffers and culture plate coating reagents 
Dulbecco's PBS buffer (PBS: Ca2+/Mg2+ free) was prepared by dissolving NaCl 
(137 mM), Na2HP04 (10 mM), KCl (2.6 mM) and KH2PO4 (1.8 mM) with ddHzO. 
The solution was adjusted to pH 7.5 with 1 M NaOH, filter sterilized and stored at 
40c. 
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Laminin was freshly prepared by diluting stock solution from 0.25 mg/ml to 5 
j^g/ml with sterile PBS and added into poly-DL-omithine coated wells for at least 1 h 
at room temperature. 
Poly-DL-ornithine was prepared the day before cell dissociation by diluting stock 
solution from 25 mg/ml to 500 |ig/ml with ddHsO and added into wells of cell 
culture plates overnight at 4 
2.2.3.1 Buffers and solutions for immuno cy to chemistry 
Triton X-100 (0.3%, v/v) was prepared by adding 0.6 ml of Triton X-100 to 
199.4 ml of PBS and stored at 
Triton X-100 (0.01%, v/v) was prepared by adding 0.3 ml of Triton X-100 (0.3%) 
to 8.7 ml of PBS immediately prior to experiment. 
Blocking solution (3%, v/v) was prepared by adding 0.3 ml of normal donkey 
serum to 9.7 ml of PBS immediately prior to experiment. 
Kryofix solution was prepared by dissolving 10 g of PEG into 79 ml of absolute 
ethanol and 74 ml of ddHzO (absolute ethanol:H20:PEG300 at a ratio of 7.9:7.4:1)， 
and stored at 4 ‘ 
Acetone and methanol (1:1) solution was prepared by adding 10 ml of acetone to 
10 ml of methanol and stored at 4 
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Paraformaldehyde (4%, w/v) was prepared by dissolving 0.48 g of 
paraformaldehyde in 8 ml of ddUjO with 80 of 1 M NaOH at 60 ''C. Then, the 
solution was removed from heat and was supplemented with 4 ml of 3X PBS. 
3X Dulbecco，s PBS (3X PBS: Ca^ /^Mg^ '' free) was prepared by dissolving NaCl 
(411 mM), Na2HP04 (30 mM), KCl (7.8 mM) and KH2PO4 (5.4 mM) with ddHzO. 
The solution was adjusted to pH 7.5 with 1 M NaOH, filter sterilized and stored at 
Mounting medium (90% glycerol) was prepared by mixing 18 ml of glycerol with 
2 ml of ddHzO and stored at room temperature. 
2.2.3.2 Buffers and solutions for assay of [^H]cAMP production 
HEPES-buffered saline (HBS) buffer was prepared by dissolving HEPES (15 mM), 
NaCl (140 mM), KCl (4.7 mM), CaCl2.2H20 (2.2 mM), MgCl2-6H20 (1.2 mM) and 
KH2PO4 (1.2 mM) in ddUjO. The buffer was adjusted to pH 7.4 with 1 M NaOH, 
filter sterilized and stored at 4 °C. 
Washing Buffer was prepared by adding glucose (3.3 mM) to HBS immediately 
before cAMP assay. 
• 
Assay Buffer was prepared by adding IBMX (1 mM) into washing buffer 
immediately prior to experiment. 
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Imidazole solution (0.5 M) was prepared by dissolving 104.5 g of imidazole 
powder and 29 g of NaOH in ddHsO. The solution was adjusted to pH 7.5 with 1 M 
NaOH, made up to 2 L and stored at room temperature. 
Imidazole solution (0.1 M) was prepared by diluting 400 ml of 0.5 M Imidazole 
solution with 1600 ml of ddHsO and stored at room temperature. 
Hydrochloric acid (4 M) was prepared by diluting 330 ml of 12.1 M HCl to 670 ml 
of ddHzO and stored at room temperature. 
Hydrochloric acid (1 M) was prepared by diluting 500 ml of 4 M HCl to 1500 ml 
of ddH20 and stored at room temperature. 
Stop solution (10% TCA with 2 mM ATP) was prepared by dissolving ATP (2 
mM) with 10% TCA. The stop solution was freshly prepared and temporary kept at 
4 until use. 
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2.3 Antibodies used for identifying DRG cells 
2.3.1 Primary antibodies 
Antibody Host Type Supplier Catalog number 
CNPase Mouse Monoclonal IgG Millipore MAB326 
GalC Rabbit Polyclonal IgG Sigma G9152 
GFAP Mouse Monoclonal IgG 1 Sigma G6171 
GLAST Guinea Pig Polyclonal IgG Chemicon AB1783 
GS Mouse Monoclonal IgG2a Chemicon P20749 
Sioop Mouse Monoclonal IgG 1 Sigma S2532 
SK3 Rabbit Polyclonal IgG Alomore APC025 
Thyl . l Mouse Monoclonal IgM Sigma M7898 
TUJ-1 Rabbit Polyclonal IgG Sigma T2200 
2.3.2 Secondary antibodies 
Antibody Supplier Catalog number 
Alexa Fluor 647 anti-mouse IgG Invitrogen A21463 
Alexa Fluor 647 anti-rabbit IgG Invitrogen A31573 
FITC anti-guinea pig IgG Jackson 706-095-148 
Immunoresearch 
FITC anti-mouse IgG Jackson 715-095-150 
Immunoresearch 
FITC anti-mouse IgG subtype Fey Jackson 115 095 206 
subclass 2a specific Immunoresearch 
T A/r u • Jackson 715-095-140 FITC anti-mouse IgM u chain specific , , Immunoresearch 





3.1 Preparation of DRG cell cultures 
All experiments were performed under license from the Government of the Hong 
Kong SAR and approval by the Animal Experimentation Ethics Committee of the 
Chinese University of Hong Kong. The dorsal root ganglia were removed from all 
levels of the spinal cord of male Sprague—Dawley rats (150-200 g) and cultures were 
prepared as described previously (Ng et al., 2010). Briefly, rats were deeply 
anaesthetized with pentobarbitone (135 mg/kg, i.p.). The whole spinal column was 
dissected out from rostral end of the hind legs to the base of the skull. Excess tissue 
was removed with the use of small scissors and rongeurs to expose the dorsal side of 
the vertebra. The spinal cord was exposed by cutting a strip of bone from the dorsal 
roof of the vertebral column using Malleus Nippers. Using Vannas curved spring 
scissors and fine forceps, dorsal root ganglia were dissected out and placed 
immediately in complete Ham's F14 medium, followed by incubation with 0.125% 
collagenase for 3 h and with 0.25% trypsin for 30 min in serum-free Ham's F14 
medium. The dorsal root ganglia were then resuspended in DNase I (0.44 mg/ml) 
< 
and soybean trypsin inhibitor (0.55 mg/ml), and dispersed by series of triturations 
using a flame-polished salinized Pasteur pipette. The cell suspension was centrifiiged 
through a cushion of BSA (15%) to eliminate much of the myelin and cellular debris. 
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After that, the supernatant was aspirated and the cell pellet was resuspended in 
complete Ham's F14 medium. Morphologically distinct phase-bright neurons and 
phase-dark glial cells were counted using a hemocytometer slide. Cells were 
typically seeded at 5000 neurons per well onto 24-well tissue culture plates pre-
coated with poly-DL-omithine (500 |a,g/ml) and laminin (5 |j.g/ml) and assayed after 
two days in culture in an atmosphere of 5% CO2 at 37 for immunocytochemical 
and cAMP studies. 
3.2 Preparation of neuron-enriched and glial cell cultures 
To prepare neuron-enriched cell cultures, mixed DRG cells were plated onto poly-
DL-omithine coated 10-cm tissue culture dishes (with a maximum of cells from two 
rats per dish), as described in Lindsay (1988). After an overnight incubation, the 
loosely attached neuronal cells were gently removed from the more firmly attached 
glial cells by a repetitive stream of F14 medium (4 ml) delivered using a flame-
polished salinized Pasture pipette. 
The remaining glial cells on the 10-cm tissue culture dishes were harvested after 
incubation with 1 ml of trypsin (0.05% in PBS) for 1 min at 3 7 � C with 5% CO2. 
DRG neurons and glial cells (small phase-dark cells) were counted using a 
hemocytometer slide. Neurons and glial cells were seeded onto poly-DL-
omithine/laminin-coated 24-well tissue culture plates at a density of 5000 neurons 
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per well and 10000 glial cells per well, respectively. Neuron-enriched cells and glial 
cells were assayed after one day in culture for immunocytochemical and cAMP 
studies. Cell numbers in neuron-enriched and glial cell cultures were similar to those 
in the mixed DRG cell cultures on the day of assay. 
3.3 Immunocytochemistry 
Cells cultured on coated glass coverslips were washed twice with PBS and then 
preserved in kryofix solution (Raye et al, 2007) at 4 if immunocytochemistry 
was not performed immediately. Otherwise, coverslips with cells were washed twice 
with PBS (5 min interval between each wash) and then fixed with ice-cold 
acetone:methanol (1:1) for 20 min or with 4% paraformaldehyde (PFA) for 10 min 
at room termperature. Cells were then washed three times with PBS and incubated 
with 0.3% Triton X-100 with 3% donkey serum for 30 min to permeabilize cells and 
block non-specific antibody binding. Cells were then incubated with primary 
antibodies at 4 °C overnight, followed by secondary antibody incubation for 1 h at 
room temperature. The primary and secondary antibodies employed and sources are 
listed in Sections 2.3.1 and 2.3.2. All samples were incubated for 4 min with 
Hoechst 33342 stain (0.2 (xg/ml) to identify cell nuclei. The coverslips were mounted 
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with glycerol (90%) on glass slides and imaged using an Olympus 1X51 inverted 
microscope (Center Valley, PA, USA) with Qimaging Retiga-2000R CCD camera 
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(Surrey, BC, Canada). Fluorescent images were merged using Adobe Photoshop 
CS4 (San Jose, CA, USA). 
3.4 Immunohistochemistry 
Whole dorsal root ganglia were dissected from all spinal levels of Sprague-Dawley 
rats and fixed with 4% paraformaldehyde in PBS at 4 for 24 h. The fixed DRG 
tissues were stored in sucrose solution (30% sucrose, 10% glycerol) for at least 48 h 
at 4 °C. Whole DRG were then placed in embedding medium, optimal cutting 
temperature (OCT) and frozen at -80 °C. DRG were cut into thin sections (15 |Lim) 
using a cryostat, thaw-mounted on slides and stored at -80 DRG sections were 
incubated in 0.01% Triton X-100 for 15 min and then with blocking solution for 30 
min at room temperature. DRG sections were then incubated with primary 
antibodies at 4 °C overnight, followed by secondary antibody incubation for 1 h at 
room temperature. The primary and secondary antibodies employed and sources are 
listed in Sections 2.3.1 and 2.3.2. All samples were incubated for 4 min with 
Hoechst 33342 stain (0.2 jig/ml) to identify cell nuclei. The glass slides with whole 
DRG sections were mounted with glycerol (90%) and imaged using an Olympus 
1X51 inverted microscope (Center Valley, PA, USA) with Qimaging Retiga-2000R 
I 
CCD camera (Surrey, BC, Canada). Fluorescent images were merged using Adobe 
Photoshop CS4 (San Jose, CA, USA). 
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3.4 Determination of [^H]cAMP production in DRG cells 
3.4.1 Principle of assay 
The adenylyl cyclase activity was determined by loading DRG cells with 
[^H]adenine which is converted to [^H]ATP inside the cells. When adenylyl cyclase 
is stimulated, [^H]ATP is converted to [^H]cAMP. Breakdown of [^H]cAMP was 
prevented by incubating cells with IBMX (a phosphodiesterase inhibitor) so that the 
accumulation of [^H]cAMP was measured. [^H]cAMP was then separated from other 
tritium-labeled adenine derivatives ([^H]AXP), including [^H]ATP and [^H]ADP, 
using Dowex-Alumina column chromatography. The [^H]cAMP production in the 
presence of IBMX reflects the activity of adenylyl cyclase (Barber et al, 1980). 
3.4.2 Loading DRG cells with [^H]adenine 
To determine the total cAMP production in DRG cell cultures, cells were washed 
with 1 ml of F14 medium and incubated with 0.5 ml of complete F14 medium 
containing [^H]adenine (2 |LiCi/ml; 1 |iCi/well) for 16 h before the [^H]cAMP assay. 
3.4.3 Column preparation 
Dowex AG50W-X4 resin columns were washed with 10 ml of distilled water before 
use. After use, these columns were washed with three washing cycles with 4 ml of 1 
M HCl followed by 10 ml distilled water. The alumina columns were washed with 8 
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ml of 0.1 M imidazole solution before use. After use, the columns were washed four 
times with 8 ml of 0.1 M imidazole solution. 
3.4.4 Measurement of [^H]cAMP production in DRG cells 
On the assay day, cells were washed twice with 1 ml of washing buffer and 
incubated with 0.5 ml assay buffer (HBS containing 1 mM IBMX) in the presence or 
absence of antagonists for 15 min followed by 30 min incubation with agonist at 
37 in assay buffer. Treatment was stopped by addition of 0.5 ml of ice-cold stop 
solution (10% TCA with 2 mM ATP). Then, the samples were left on ice for at least 
1 h for the extraction of [^H]cAMP and other tritium-labeled adenine derivatives. 
This method measures both intracellular and extracellular [ H]cAMP. 
[3h]cAMP was isolated from other [^H]adenine nucleotides using column 
chromatography. Firstly, the Dowex columns were placed over scintillation vials. 
Then samples (in 1 ml 10% TCA extracts) were loaded on to the columns followed 
by 3 ml of distilled water to elute the [^H]AXP into the scintillation vials. The eluate 
was mixed thoroughly with 7 ml of scintillant (OptiPhase ’Hi-safe’ 3). 
The Dowex columns were then placed over the alumina columns. The remaining 
[^H]cAMP fraction was eluted with 10 ml of distilled water. When water had 
completely run through both set of columns, the alumina columns were already 
loaded with [^H]cAMP fraction. Then, the alumina columns were placed over 
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another set of scintillation vials and fH]cAMP was eluted by 6 ml of 0.1 M 
imidazole solution. At last, the eluate was mixed thoroughly with 10 ml of scintillant 
(OptiPhase 'Hi-safe' 3). 
In parallel to test samples, blank samples (a mixture of 0.5 ml assay buffer and 
0.5 ml stop solution) were also added to the columns and processed the same way as 
for samples for the determination of the background count of the columns. The value 
obtained was subtracted from all the test values. The radioactivity of samples was 
measured by liquid scintillation counting (Packard LS2900TR). 
3.4.5 Data analysis 
The production of [ HJcAMP from cellular [ H]ATP was estimated as the ratio of 
radiolabelled cAMP to total AXP, and was expressed as x 100% (i.e. % 
conversion) (Salomon, 1991). For the characterization of Gg-GPCRs, the percent 
inhibition of the agonist-stimulated response by the antagonist was calculated as: 
1 (response of agonist in the presence of antagonist - basal) � 
(response of agonist alone - basal) 
All assays were performed in duplicate. Comparison between groups were made 
using ANOVA (analysis of variance) with Bonferroni's post hoc test. Statistical 
f 
significance was taken asp < 0.05. 
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Chapter 4 
Identification of DRG cells in dissociated cultures 
4.1 Introduction 
There is considerable interest in the use of dissociated cultures of DRG cells for the 
study of the properties of individual neurons and the underlying mechanism of 
increased excitability in response to nerve injuries. Much about the .process of pain 
development has been learnt from in vitro studies using DRG cells. For example, the 
isolated small diameter neurons have been used as a model for electrophysiology 
studies to investigate pain processes in cell cultures (Gold et al, 1996; Harper et al., 
1985). Moreover, recent evidence shows that the glial cells, which are in close 
association with neurons, modulate pain development and processing directly by 
sensitizing neurons following nerve injury (Capuano et al., 2009). An advantage of 
studying DRG cells in culture is that DRG cells can be studied separately in cultures 
with the aid of cell separation techniques. For instance, neurons and non-neuronal 
cells in a mixed DRG cell population can be isolated in cultures, in which the 
investigation on the activity of a particular type of cell with another type of cell 
t 
becomes readily available. 
Morphologically, DRG neurons can easily be distinguished from the non-neuronal 
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cells based on the cell sizes under the view of phase-contrast microscope at a low 
magnification. However, whether a certain non-neuronal cell is a SGC, Schwann cell 
or fibroblast cannot be judged simply by its morphology because there are currently 
no well-defined and consistent descriptions of different non-neuronal cells in both 
live and fixed cell cultures. In living cultures, TG SGCs were defined as small, dark 
cells with an elongated shape (Capuano et al., 2009). While in fix and stained 
cultures, TG SGCs were described as having a fusiform shape whereas fibroblasts 
were flat cells with an large elongated nucleus (Ceruti et al, 2011). In another study, 
DRG SGCs and Schwann cells were distinguished by recognizing SGCs as being 
multipolar while Schwann cells as being predominately spindle shaped, small 
bipolar or tripolar (Ahmed et al, 2009). As the study of neuron-glia interactions 
requires the ability to identify the subtypes of non-neuronal cells, the use of 
immunocytochemical methods to identify DRG cells using cell type-specific 
antibodies is useful. 
DRG neurons in vitro are commonly identified using antibodies against class III p-
tubulin (TUJ-1) (Backstrom et al., 2000; Ng et al, 2010)，while non-neuronal cells, 
including SGCs, Schwann cells and fibroblasts, are identified by many different cell 
type-specific antibodies. However, a majority of these antibodies were used in 
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immunohistochemical studies (Jasmin et al, 2010; Zhang et al, 2009) but rarely in 
in vitro cell-based studies (Capuano et al, 2009; Ceruti et al, 2011). 
In the study of DRG cells in vitro, by the use immunocytochemical method, we 
looked for antibodies that recognize antigenic markers which are expressed on a 
specific type of DRG cells. Glial fibrillary acidic protein (GFAP) is an antigenic 
marker for DRG glial cells. A low level of GFAP expression on DRG glial cells was 
reported in vivo during normal state and the expression of GFAP was found to be 
increased upon activation such as following nerve injury (Vit et al.’ 2006). GFAP is 
therefore frequently used as a marker of glial cell activation (Xie et al., 2009; Zhang 
et al, 2009). To specifically identify SGCs, many different antibodies have been 
used, including antibodies that recognize SGC-specific glutamate transporter, 
GLAST (Ohara et aL, 2008), small-conductance Ca '^^ -activated K"^  channel, SK3 
(Vit et aL, 2006), and GS (Hanani, 2005). For Schwann cells, antigenic markers such 
as galactocerebroside (GalC) (Sobue et al, 1986)，SIOOP (Campana, 2007), and 
CNPase (Toma et al, 2007) have been used. For fibroblasts, anti-Thy-1 antibody 
(Fields, 1980) has been used. 
It is common to use immunocytochemical methods to characterize cultured cells. 
The uses of preservative and different fixatives have been adapted to work, with the 
immunocytochemical methods. Preservatives, such as kryofix preserve cells (Khaira 
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et al., 2009; Raye et aL, 2007), were used in order to add flexibility on when 
immunocytochemistry is performed. The roles of fixation are to maintain cellular 
structure, retain antigenicity and prevent autolysis, and thus aid antibody binding 
(St-Laurent et al, 2006). Two commonly used fixatives are acetone methanol (1:1) 
solution and 4% PFA solution. The two fixatives have different fixation mechanisms 
to aid antibody binding. The acetone methanol (1:1) solution fixes cells by 
denaturing and modifying the tertiary structure of proteins while preserving 
antigenic sites for antibody binding (St-Laurent et al., 2006). PFA solution, on the 
other hand, fixes cells by insolubilizing intracellular substances such as 
carbohydrates, lipids and nucleic acids and forming cross-link protein molecules by 
forming covalent bonds. Different immunochemical methods may give different 
fluorescence patterns and intensities. These may affect subsequent interpretation of 
immunoreactive cells and hence, an optimal method of fixation often needs to be 
determined for each cellular marker (St-Laurent et al.，2006). Using adequate 
preservative and fixation methods are therefore important for immunocytochemical 
analysis. 
4.2 Aim of study 
Isolated DRG cell cultures contain a mixture of neurons and non-neuronal cells 
including SGCs, Schwann cells and fibroblasts. To fully study the properties and 
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interactions among DRG cells, it is necessary to distinguish the neurons and 
different glial cells from one another. With the different antigenic markers available 
for the identification of various DRG cells, the aim of this study was to identify the 
types of non-neuronal cells including glial cells (SGCs and Schwann cells) and 
fibroblasts present. 
4.3 Results 
4.3.1 Identification of DRG cells in isolated cultures 
A typical dissociated DRG cell culture contains a mixture of neurons and non-
neuronal cells. This mixture of cells could be identified under the view of phase-
contrast microscope (Fig. 4.1 A). DRG neurons were identified in cultures with larger, 
spherical and phase-bright appearance (arrows) while non-neuronal cells were 
identified with smaller, elongated and phase-dark appearance (arrow heads). The 
preparation of neuron-enriched cell cultures eliminated over 70% of the proliferating 
non-neuronal cells, while the preparation of glial cell cultures eliminated over 99% 
of neurons. On day 2, the estimated purity of neurons was 20% in mixed DRG cells 
and was around 40% in neuron-enriched cells (Fig. 4.1 A and B). The estimated 
purity of glial cells was over 99% in glial cell cultures (Fig. 4.1C). To control the 
proliferation of contaminating glial cells, we have previously incubated neuron-
containing cells with arabinoside C (10 pM), 5-fluro-2‘-deoxyuridine (50 i^M) and 
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uridine (150 |LIM) but these drugs failed to produce marked effect on limiting glial 
cell numbers. 
To characterize different DRG cells in cultures, various antibodies that recognize 
antigenic markers on neurons, glial cells and fibroblast were used. Anti-TUJ-1 
antibodies were used for the identification of DRG neurons, anti-GFAP antibodies 
were used to identify activated glial cells, and Hoechst 33342 stains were used to 
label cell nuclei (Fig. 4.2). All neurons and the associated neurites were 
immunoreactive for TUJ-1 (red) while activated glial cells were immunoreactive for 
GFAP (green). GFAP-immunoreactive glial cells were grouped into two broad 
morphological categories. The first group had a round nucleus and spreading 
cytoplasm (Fig. 4.2F; arrows) and the other group had an elongated nucleus with a 
spindle shape and was bipolar or multipolar with fine projections (arrow heads). 
TUJ-1- and GFAP-negative cells were identified with Hoechst 33342 stain, in which 
only cell nuclei were stained blue (asterisks). 
4.3.2 Activation and proliferation of glial cells in isolated cell cultures 
GFAP is frequently used as a marker of glial cell activation. With this characteristic, 
I 
the activation and proliferation of glial cells in the three DRG cell cultures were 
assessed over five days in culture. As neuron-enriched cells and glial cells were 
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prepared one day after the mixed DRG cell cultures, representative images of 
neuron-enriched and glial cells were shown from day 2. Glial cells proliferated over 
time in all three cultures as indicated by the increase of blue cell nuclei (Fig. 4.3). 
Comparing the representative fluorescence images of mixed DRG cells on day 1 and 
day 5 (Fig. 4.4A-B), it suggested an increase in glial cell number, GFAP-
immunoreactive glial cells and fluorescence signal intensity of GFAP. For cell 
quantification analyses, two fluorescence images from random fields were taken at 
20 X magnification and over 100 cells per image were counted in a double-blinded 
manner. This preliminary study (n = 1) showed the increase in glial cells number 
over the time in all the cell cultures (Fig. 4.4C). Quantifying the GFAP-
immunoreactive glial cells, the percent of GFAP-immunoreactive glial cells was 61 
士 50/0 in mixed cell, 33 士 6o/o in neuron-enriched cells and 44 士 4o/o in glial cells on 
day 2 (Fig. 4.4D). The percent of GFAP-immunoreactive glial cells increased over 
time, showing 80 士 3% in mixed cells, 74 士 1% in neuron-enriched cells and 70 士 
2% in glial cells on day 5. Besides, glial cells with absent, low or high GFAP 
fluorescence intensity in the mixed DRG cells were assessed by scoring the GFAP 
fluorescence intensities from 0 to 9, where 0 represented absence of GFAP 
characteristics, 1 - 4 represented low GFAP fluorescence intensity and 5 - 9 
represented high GFAP fluorescence intensity. Two representative images of day 1 
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and day 5 (Fig. 4.4E) were assessed with naked eye in a double-blinded manner. 
Results indicated that not only did the percent of GFAP-immunoreactive glial cells 
increase, the GFAP fluorescence intensity of activated glial cells was also shown to 
increase over time. In mixed cells on day 1, the majority of glial cells (53 士 6o/o) 
were GFAP-negative, with only 4 士 P/o of glial cells showing high GFAP 
fluorescence intensity. The GFAP fluorescence intensity increased over time, in 
which 13 ± 3% of glial cells were GFAP-negative and 58 士 6o/o of glial cells showed 
high GFAP fluorescence intensity on day 5. Neuron-enriched and glial cell cultures 
demonstrated the similar pattern of increasing GFAP fluorescence intensity of glial 
cells over time. 
4.3.3 Identification of glial cells in cultures 
The isolated DRG cell cultures contained mixtures of neurons and glial cells. The 
use of GFAP antibodies identified only a portion but not all glial cells, GFAP-
negative cells could be SGCs, Schwann cells or fibroblasts. To identify the different 
non-neuronal cells in isolated DRG cultures, different non-neuronal cell-specific 
antibodies were used. For the identification of SGCs in dissociated DRG cell 
cultures, antibodies against antigenic markers expressed on SGCs were used. In 
addition to antibodies against GFAP (Fig. 4.5), SGC-specific antibodies against 
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GLAST (Fig. 4.6), GS (Fig. 4.7) and SK3 were used (Fig. 4.8). For the identification 
of fibroblasts, antibodies against Thyl.l were used (Fig. 4.9). For the identification 
of Schwann cells, antibodies against Schwann cell-specific antigenic markers such as 
CNPase (Fig. 4.10), SlOOp (Fig. 4.11) and GalC (Fig. 4.12) were used. Despite the 
wide use of these antibodies on DRG or TG sections, many of these antibodies have 
rarely been used in DRG cell cultures. The dilutions of antibodies used in this study 
were referenced from previous studies that identified different non-neuronal cells in 
sections or cell cultures of DRG or TG. In this study, except for GFAP antibodies 
that produced specific staining pattern (Fig. 4.5D) in vitro, all other antibodies 
against non-neuronal cell-specific antigenic markers tested on mixed DRG cells 
were detected on both neurons and non-neuronal cells with no specific binding 
patterns when fixed with acetone methanol (1:1) solution. For example, although 
GLAST is antigenic protein that had been shown to be expressed in vivo on SGCs 
only, antibodies against GLAST were detected on both neurons (Fig. 4.6D; arrows) 
and non-neuronal cells (arrow heads) generating no specific and sharp staining 
pattern in vitro. Either increasing or decreasing the antibody dilutions relative to the 
suggested dilution did not enhance the specificity of the binding of antibodies (data 
not shown). Incubations with other non-neuronal cell-specific antibodies showed 
similar non-specific staining patterns. The binding of non-neuronal cell-specific 
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antibodies on DRG neurons and non-neuronal cells prevented the identification of 
glial cell subtypes and fibroblasts in dissociated cultures. Pure fibroblasts isolated 
from adult rat cardiomyocytes were kindly provided by Ms Jessica Law (CUHK). 
These fibroblasts were stained with anti-Thyl.l antibodies (Fig. 4.9F). Fibroblasts 
were fixed with acetone methanol (1:1) solution without kryofix. All fibroblast were 
labelled with anti-Thyl.l antibodies revealing its irregular cell shape, large and 
spread cytoplasm. Assuming that any fibroblasts in isolated DRG cell cultures had 
similar morphology as what was seen in Fig. 4.9F, it was suggested that there were 
no fibroblasts in our isolated DRG cell cultures. 
4.3.4 Modification of staining methods 
In an attempt to produce specific staining patterns for the non-neuronal cell-specific 
antibodies for the identification of glial cell subtypes and fibroblasts in isolated 
cultures, the effect of using cell preservative and different fixatives was studied. The 
use of a cell preservative, such as kryofix, preserves cells and adds flexibility to 
when immunocytochemistry is performed. Our previous studies used kryofix 
solution to preserve cells and stain cells with anti-TUJ-1, -GFAP, -CGRP,- IB4, -IP 
I 
and EP4 and -Trk A antibodies (Ng et al, 2011; Ng et al, 2010) without suggesting 
any problem with the use of kryofix solution. However, to our knowledge, the effect 
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ofkryofix solution on specific antibody binding in DRG cells has not been evaluated. 
As a result of that, we studied the effect of kryofix on specific antibody binding by 
incubating DRG cells with kryofix for 4 h (kryofix-treated group) before fixing cells 
with acetone methanol (1:1) solution. The staining patterns and fluorescence 
intensities of non-neuronal cell-specific antibodies were compared with those of the 
DRG cells without incubation with kryofix (control group). Results indicated that 
among all the non-neuronal cell-specific antibodies tested, neither kryofix-treated 
group nor control group produced specific antibody binding patterns (Fig. 4.5-4.12, 
D-E). Non-neuronal cell-specific antibodies were detected on both neurons and non-
neuronal cells in both control and kryofix-treated groups. Comparing the 
fluorescence intensities of GFAP antibodies between the two groups, GFAP-
immunoreactive glial cells in the kryofix-treated group were not as sharp as and as 
bright as those in the control group (Fig. 4.5D-E). This indicated that in general, 
kryofix treatment reduced antibody binding and hence reduced the ability to identify 
immunoreactive cells and their shape for glial cell subtype identification. As a result, 
the use ofkryofix to preserve DRG cells is not recommended. 
We have previously showed the presence of EP4 and IP receptors on DRG neurons 
and glial cells using 4% PFA solution (Ng et al., 2010). The effect on the use of 
different fixatives including acetone methanol (1:1) solution and 4% PFA solution, 
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effects were therefore studied and compared. Both groups of cells that were fixed 
with acetone methanol (1:1) solution and 4% PFA solution gave non-specific binding 
patterns (Fig. 4.5-4.12, C-D). Except for anti-GFAP antibodies, all other antibodies 
labelled both neurons and glial cells that prevented the identification of different 
glial cells and fibroblasts. Comparing the two fixatives, the fluorescence signals of 
GFAP-immunoreactive glial cells were weaker and less distinct when fixed with 4% 
PFA solution when compared with acetone 1:1 solution (Fig. 4.5C-D). The results 
suggested that fixing DRG cells with acetone methanol (1:1) solution produced 
stronger and more distinct fluorescence signal, therefore the use of acetone methanol 
(1:1) solution is recommended over 4% PFA solution as DRG cell fixative. 
4.3.5 Immunohistochemistry to identify DRG cells in DRG slices 
Results indicated that the use of immunocytochemical methods could not lead to the 
identification of the different types of glial cells and fibroblasts in isolated cultures. 
With the wide use of non-neuronal cell-specific antibodies in DRG sections, these 
antibodies were tested in DRG cell sections to identify different glial cells and 
fibroblasts (Fig. 4.5-4.12, A-B). As the different types of glial cells and fibroblasts 
I 
are confined in distinct locations, the specificities of different antibodies against 
different types of non-neuronal cells could be evaluated. As expected, GFAP 
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immunoreactivity (Fig. 4.5B) was not detected on whole DRG acutely isolated from 
uninjured rat. All the antibodies against SGC-specific markers, including GLAST, 
GS and SK3 were detected on SGCs but not on neurons and Schwann cells of DRG 
sections as expected (Fig. 4.6-4.8，B). As indicated by the fluorescence images, 
SGCs could be identified by the immunoreactive cells that were around the cell body 
of neurons (Fig. 4.6B; arrow heads). Neurons were not labelled with antibodies 
against SGC-specific markers (arrows). Schwann cells were confined in regions 
enriched with nerve fibres (asterisk) and these cells were not labelled with the 
antibodies against SGCs. Fibroblasts, on the other hand, made up the capsule of the 
DRG and were found on the outer region. However, all antibodies specific for SGCs 
were also detected on the outer region of whole DRG. The antibodies against 
fibroblast-specific marker, Thy 1.1, were detected on both neurons (Fig. 4.9B; arrows) 
with weak fluorescence intensity. Antibodies against Schwann cell-specific markers 
including CNPase, SlOOp and GalC showed different binding patterns on DRG 
sections (Fig. 4.10-4.12，B). Anti-SlOOp antibodies were detected on SGCs and the 
outer region of DRG but were not detected on neurons and Schwann cells (Fig. 4.11). 
Anti-CNPase (Fig. 4.1 OB) and anti-GalC (Fig. 4.12B) antibodies were detected on 
( 
neurons, SGCs, Schwann cells and fibroblasts in DRG sections. 
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4.3.6 Comparison of antibody staining in whole DRG and isolated DRG cells 
The staining pattern of different non-neuronal cell-specific antibodies varied in 
isolated cultures and DRG sections. Anti-GFAP antibodies were detected on 
activated glial cells in isolated cultures but were not detected on whole DRG sections, 
as expected (Fig. 4.5). Besides, as shown in Fig. 4.6-4.8，antibodies against SGCs 
failed to identify SGCs in isolated cultures but produced a specific staining pattern in 
tissue sections. For example, while anti-GLAST antibodies were detected on neurons 
and non-neuronal cells in isolated cultures (Fig. 4.6C-E), anti-GLAST antibodies 
were detected in SGCs but not on neurons and Schwann cells in DRG sections (Fig. 
4.6B). Such staining patterns were also seen with the other antibodies against SGCs 
including anti-GS antibodies (Fig. 4.7) and anti-SK3 antibodies (Fig. 4.8). These 
antibodies allowed identification of different glial cells in DRG sections but not 
isolated cultures. Antibodies against Schwann cell-specific and fibroblast-specific 
markers did not help identifying the different glial cells and fibroblasts in either 
isolated cultures or sections (Fig. 4.9-4.12). 
4.4 Discussion 
I 
The DRG neurons and non-neuronal cells were readily distinguished in isolated live 
cell cultures using phase-contrast microscopy and were distinguished in fixed cell 
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cultures using immunocytochemical methods. When viewed under phase-contrast 
microscope, neurons were the large phase bright cells while non-neuronal cells were 
the small phase dark cells. Using immunocytochemical methods, TUJ-1 antibody 
recognized all DRG neurons of different sizes and their associated neurites with high 
specificity. The use of GFAP antibodies revealed the different morphologies of 
activated glial cells in cultures. A majority of activated glial cells could be broadly 
classified into two morphological classes including the first class of activated glial 
cells baring a round nucleus and spread cytoplasm and the other class had an 
elongated nucleus and spindle shape, and was bipolar or multipolar with fine 
projections. With a longer incubation period (> four days in culture), it was observed 
from the fluorescence images that more glial cells were classified as cells baring 
flattened nucleus, spindle shape, bipolar or multipolar with fine projections. 
However, after four days, the density of glial cells was too intense to study clearly 
the different morphologies of individual glial cells and therefore, quantification of 
the morphologies cannot be easily achieved. In order to investigate this phenomenon 
further, live cell microscopy is needed to visualize and trace the proliferation and 
changes of glial cell morphologies over time in cultures at a lower cell density. By 
I 
doing this, it helps clarify whether (1) glial cells with a particular type of 
morphology proliferate faster than the other type or (2) the morphology of a 
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particular type of glial cells changes to the other type over time in culture. 
Nevertheless, the glial cells in all three DRG cell cultures proliferated over five days 
in culture. The increased glial cell proliferation in cultures over time is another piece 
of evidence to support the hypothesis that isolated DRG cell cultures mimics 
neuropathic pain state (LaMotte, 2007), as increased glial cell proliferation has also 
been reported in whole DRG after nerve injury (Elson et al, 2004). 
Other than proliferation of glial cells in isolated cultures, glial cells in the three cell 
cultures expressed GFAP, a marker for glial cell activation. Increased GFAP 
expression has been reported after nerve injury of whole DRG (Xie et al., 2009). 
With our results that indicated no GFAP expression in whole DRG section acutely 
dissociated from uninjured rat but an increased expression over time in isolated 
cultures, these ftirther suggested that isolated DRG cultures may mimic neuropathic 
pain states (Xie et al, 2009; Zhang et al., 2009). The proportions of GFAP-
immunoreactive glial cells increased over time and over 70% of total glial cell 
population was GFAP-positive in all the three cell cultures after five days. The 
proportions of GFAP-immunoreactive cells were larger in neuron-containing cultures 
i 
than in pure glial cell cultures from day 2 to day 5. These results suggested that glial 
cell activation in cultures over time was likely to depend on the presence of neurons. 
Furthermore, the fluorescence intensities of GFAP-immunoreactive glial cells 
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increased over time in mixed DRG cells and in neuron-enriched cells and pure glial 
cells. The fluorescence intensity of GFAP-immunoreactivity is reported to reflect the 
amount of GFAP fairly well (Norton et al, 1992) therefore our result suggested that 
the amount of GFAP being produced in glial cells increased over time in cultures. 
We demonstrated that not only did the number of GFAP-immunoreactive glial cells 
increase, but the amount of GFAP being produced also increased over time in culture. 
Taken together, the physiological characteristics of glial cells in isolated cultures 
were similar to that of glial cells in neuropathic pain conditions. For example, our 
dissociated DRG glial cells proliferated in cultures while this observation has also 
been reported in vivo after nerve injury (Elson et al., 2004). Besides, dissociated 
DRG glial cells expressed GFAP over time in cultures and this characteristic has also 
been suggested in vivo after nerve injury (Xie et al, 2009). It is therefore reasonable 
to suggest that DRG cells in isolated cultures may mimic neuropathic pain models in 
vivo. In isolated cultures, neurons are axotomized and this condition is similar to 
what happens in neuropathic pain models in vivo. Injured neurons may trigger or 
prevent the release of factors leading to activation and proliferation of glial cells that 
leads to neuropathic pain (Hanani, 2005). : 
Antibodies against GFAP were used in the identification of glial cells in this study. 
However, there are some drawbacks with the use of GFAP. First and foremost is that 
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GFAP cannot serve as a cell marker for distinguishing SGCs from Schwann cells in 
DRG cell cultures. We have previously obtained nestin-positive Schwann cells (a gift 
from Prof. Daisy Shum, HKU) and demonstrated that Schwann cells were 
immunoreactive for GFAP (unpublished data). Besides, there is evidence that, non-
myelinating Schwann cells also express GFAP (Jessen et al, 1984; Mosahebi et al, 
2001; Norton et al.’ 1992). In in vivo study, SGCs and Schwann cells can be 
distinguished based on their locations relative to neurons in intact DRG, so there is 
normally no trouble with identifying SGCs and Schwann cells. However, in isolated 
cultures, there is still no clear way for the identification of GFAP-immunoreactive 
SGCs and Schwann cells. Besides, GFAP is primarily used as a glial cell activation 
marker, and it is undetectable in normal DRG glial cells (Norton et al., 1992) and the 
expression is increased only upon activation (Xie et al, 2009). As a result of that, it 
should be noted that morphologies assessed in this study were based on the 
quantification of GFAP-immunoreactive (or as defined as activated) glial cells 
including both GFAP-immunoreactive SGCs and Schwann cells. The identity of 
GFAP-negative cells remains to be confirmed. 
To distinguish SGCs, Schwann cells and fibroblasts in isolated DRG cell cultures, 
various antibodies were used in this study. However, the antibodies against non-
neuronal cells used were not specifically detected on a subtype of glial cells or 
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fibroblasts. Instead, these antibodies bound to both neurons and other glial cells. For 
example, GLAST and GS are the two proteins responsible for transporting glutamate 
from extracellular space into glial cell body for the conversion into glutamine. These 
proteins were found exclusively in SGCs in whole DRG (Hanani, 2010; Ohara et al, 
2008) and they were not known to be present in neurons. However, anti-GLAST and 
anti-GS antibodies were also detected on both neurons and non-neuronal cells in 
vitro. These results suggested that the antibodies tested were either" non-specific or 
that the antigens (GLAST and GS proteins) were expressed on neurons in isolated 
cultures. 
When compared with the specific and sharp staining pattern produced by anti-GFAP 
antibodies that allowed the recognition of the shapes of activated glial cells, the other 
non-neuronal cell-specific antibodies labelled both neurons and glial cells with very 
weak and faint signals, preventing the identification of immunoreactive non-
neuronal cells and their cell morphologies. In an attempt to improve the antibody 
binding for the identification of glial cells, we adapted different immunochemical 
methods that are commonly used. Firstly, we investigated if the preservation of cells 
in kryofix for 4 h would affect the specificity of antibody binding and the 
corresponding signal intensity. The use of kryofix to preserve cells has been used in 
immunocytochemistry protocols (Khaira et al, 2009; Ng et al, 2011; Ng et al.’ 2010; 
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Raye et al., 2007). However, to our knowledge, there are currently no reports on the 
effect of kryofix on specific antibody binding. The use of kryofix did not enhance 
the specific binding of antibodies but reduced the fluorescence signal intensity of the 
anti-GFAP and anti-CNPase antibodies. Generally speaking, the use of kryofix to 
preserve cells is not recommended. Other than the use of preservative, the method 
of fixative was also tested and compared. Results suggested that neither of the 
fixatives allowed any of the non-neuronal cell-specific antibodies to produce specific 
antibody binding patterns for the identification of subtypes of glial cells and 
fibroblasts in cultures. Comparing the two fixatives, the use of acetone methanol (1:1) 
solution generally gave sharper and more distinct fluorescence signals that the use of 
4% PFA solution. Therefore, the use of acetone methanol (1:1) solution as DRG cell 
fixative is recommended over 4% PFA solutions. Having revealed that the use of 
different fixatives and the use of kryofix had no effect in enhancing the antibody 
binding specificity, it is suggested to optimize the concentration of the blocking 
buffer to further the adaption of immunocytochemical protocol. Other studies had 
use 15% goat serum (Capuano et al., 2009) or 0.5% BSA (Capuano et al, 2009) to 
reduce non-specific binding. In this study, 0.3% donkey serum was used to reduce 
f 
non-specific binding and increasing the concentration of blocking buffer should be 
considered. 
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While we could not optimize the immunocytochemical methods to produce specific 
staining of non-neuronal cell-specific antibodies for the identification of glial cell 
subtypes and fibroblasts in isolated cultures, some of these antibodies have been 
used for identification of glial cell subtypes and fibroblasts by others (Ceruti et al., 
2008; Gladman et al., 2010; Vroemen et al., 2003). However, studies did not always 
provide the complete evidence on the binding patterns of the antibodies. For example, 
anti-SlOOp antibodies were used to identify Schwann cells in isolated DRG cell 
cultures, but no representative image of S1 OOp-immunoreactive cells was shown, 
and even without that, the author suggested that approximately 20% of DRG cells 
were Schwann cells (Gladman et al., 2010). Moreover, anti-SlOOp antibodies had 
been suggested not be an ideal marker (Hanani, 2005) because this antigen was 
shown to be present on SGCs and injured neurons of whole DRG (Vega et al., 1991). 
The same also applies to anti-CNPase and anti-Thyl.l antibodies. Anti-CNPase 
antibodies had been used to identify SGCs (Ceruti et al, 2008) and anti-Thyl.l 
antibodies have been shown to recognize both neurons and fibroblasts in cultures 
(Fields et al, 1978; Yang et al., 2008). Although the identification of glial cell 
subtypes and fibroblasts in isolated cultures would be useful to study the 
composition of different glial cells and fibroblasts in isolated DRG cell cultures, 
none of the non-neuronal cell-specific antibodies produced specific antibody binding 
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patterns for identification. This study herein suggested not to rely solely on the 
results obtained from immunocytochemical studies for cell identification purpose. It 
is also essential to optimize the staining condition for each antibody, to provide 
proper positive and negative controls for the immunostaining and to support 
immunostaining results using other methods. 
The use of non-neuronal specific antibodies in whole DRG sections produced more 
specific antibody binding patterns to identify SGCs in whole DRG. These results 
revealed that in our study, the failure of identification of isolated non-neuronal cells 
using SGC-specific antibodies was not due to the non-specificities of the antibodies, 
but may due the change of antigenic protein expression in dissociated cells cultures 
over time. This is supported by the evidence that reduced expression of protein 
mRNA of DRG cells occurred quickly after cells were isolated and plated (Franklin 
et al, 2009). Besides, the mRNA expression of glial cell-specific GS has recently 
been tested on glial cell cultures in our lab. The results that GS mRNA expression 
dropped from day 1 to day 4 revealed the decrease of the expression of this antigenic 
marker over time in cultures. 
In order to investigate the antigenic marker mRNA expression in non-neuronal cells 
with a particular morphology, one could test the presence of SGC-specific, Schwann 
cells-specific, and fibroblast-specific marker mRNA using RT-PCR that allows 
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amplification and detection of mRNA from a single cell. Then one would be certain 
whether antigenic markers of glial cells subtypes and fibroblasts were expressed in 
cultures. The use of antibodies that recognize antigenic markers specifically 
expressed on different DRG cells enables the recognition of non-neuronal cells, 
including SGCs, Schwann cells and fibroblasts, in isolated DRG cell cultures. This 
makes the identification of different DRG cells independent of cellular morphology 
in isolated cultures. The identification of different glial cells in isolated cultures is 
remained to be investigated in order to reveal the properties of different glial cells 
and any possible neuron-glia interactions. 
4.5 Summary 
In this study, the anti-TUJ-1 and anti-GFAP antibodies were used to identify neurons 
and activated glial cells in isolated cultures, respectively. The use of GFAP 
antibodies revealed the different morphologies of activated glial cells in culture. The 
majority of GFAP-immunoreactive glial cells could be broadly classified into two 
morphological classes. The first class of activated glial cells had round nucleus and 
spread cytoplasm. The second class of activated glial cells had elongated nucleus 
with spindle shape and was bipolar or multipolar with fine projection. It was also 
evident that the proliferation of activated glial cells was faster in the presence of 
neurons, revealing neuron-glia interactions where neurons influence the proliferation 
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of glial cells. Moreover, the fluorescence intensity of GFAP-immunoreactive glial 
cells increased over time in cultures, indicating that more GFAP are expressed. 
Taken together, these characteristics of glial cells in isolated cultures were similar to 
those as expressed during nerve injury and therefore, it was suggested that isolated 
cell cultures mimicked neuropathic pain models. 
Other non-neuronal cell-specific antibodies used in this study failed to produce 
specific staining patterns for the identification of glial cell subtypes and fibroblasts. 
Adapting different immunocytochemical methods did not help improve the specific 
staining patterns. However, these antibodies produced specific antibody staining 
patterns when used in whole DRG sections. These results suggested that the failure 
of giving specific staining patterns in isolated cultures was not due to the non-
specificity of the antibodies but might be due to the change of expression of 
antigenic markers of DRG cells in isolated cultures. 
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Figure 4.1 Representative phase contrast microscopic field of typical dissociated 
DRG cell cultures. Images of (A) mixed DRG cells, (B) neuron-enriched cells and 
(C) glial cells were taken after two days. Neurons (phase-bright cells; arrows) and 
( 
non-neuronal cells (phase-dark cells; arrow heads) were identified in (A). Scale bar 
represents 25 |im. 
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Figure 4.2 Identification of neurons and glial cells in dissociated DRG cell 
cultures. Representative fluorescence microscopic images of (A-B) mixed DRG 
cells, (C-D) neuron-enriched cells and (E-F) glial cells of isolated DRG cells after 
two days in cultures taken at two mangifications. Neurons were identified with anti-
TUJ-1 antibodies (1:1000; Alexa fluor 647 secondary antibodies, 1:1000; red). Glial 
cells were identified with anti-GFAP antibodies (1:500; FITC anti-mouse secondary 
antibodies, 1:500; green), illustrating spindle shaped cells with elongated nucleus (F, 
arrow heads), and cells with round and spreading cytoplasm (F, arrows). Cell nuclei 
were identified with Hoechst 33342 stain (blue, asterisk). Scale bars represent 25 i^m. 
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Characterization of GPCRs in isolated DRG cultures 
5.1 Introduction 
5.1.1 G-protein coupled receptors 
The G-protein coupled receptors (GPCRs) represent a large family of surface 
receptors which are expressed on all kinds of cells. They are essential for transducing 
external signals, such as hormones, neurotransmitters or sensory stimuli, into 
intracellular signals in response to external changes (Pierce et al., 2002). The GPCRs 
represent important therapeutic targets in drug design. The binding of a GPCR by an 
agonist or antagonist triggers or blocks the activation of the receptor that ultimately 
alters downstream signal-transduction pathways to modify intracellular systems, such 
as to regulate enzyme or ion channel activities. A GPCR classically consists of a 
seven transmembrane (7TM) domain and is associated with a heterotrimeric guanine-
nucleotide regulatory protein (G protein) (Wettschureck et al, 2005). The 7TM 
protein is composed of amino acids, which starts with an extracellular N-terminus, 
spanning across the plasma membrane seven times connected by intracellular and 
extracellular loops, and ends with an intracellular C-terminus. Although all GPCRs 
share the common feature of possessing the 7TM domain, the amino acids sequence 
of different GPCRs share almost no overall homologies (Probst et al, 1992). 
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However, significant amino acid sequence homology can be found within some 
GPCRs, which allows the classification of three major classes of GPCRs (Foord et 
al, 2005). The largest class among the three is Class A (or 1) GPCR, which 
comprises over 80% of the total GPCRs. This class of GPCRs includes hormone 
receptors, neurotransmitter receptors and light receptors, which share highly 
conserved amino acids, namely a glutamic acid/aspartic acid-arginine—tyrosine 
(E/DRY) motif, at the cytoplasmic end of the third transmembrane domain (Probst et 
al, 1992). Class B (or 2) GPCRs consist of around 25 members, which includes a 
variety of hormone receptors and neuropeptide receptors. They are mostly Gg-
coupled (discussed below) and are characterized by a large (more than 100 amino 
acid residues) extracellular domain containing several cysteines (Ulrich et al., 1998). 
Class C (or 3) GPCRs include metabotropic glutamate receptors, GABAB receptors, 
and calcium-sensing receptors. All the receptors in class C possess a very large 
extracellular domain at the amino terminus (around 500 to 600 amino acid residues) 
(Gether，2000) and this structure seems to be important for ligand binding and 
activation (Pierce et al., 2002). 
Extracellular signals are transduced by the G proteins to modulate the internal 
activity of a cell. G proteins are composed of three protein subunits: a subunit, p 
subunit and y subunit. The a subunit is associated with the 7TM receptor by covalent 
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linkage and has a GDP/GTP binding site, while P subunit and y subunit are 
associated with each other, forming an undissociable complex (Wettschureck et al, 
2005). In the unstimulated state, the a subunit of the G protein is guanine 
diphosphate (GDP) bound and is associated with the Py subunit (Gilman, 1987). 
When the 7TM receptor is bound by an agonist, the agonist induces a conformational 
change in the 7TM receptor, allowing the 7TM receptor to function as a guanine 
nucleotide exchange factor that exchanges the GDP on the a subunit with GTP. The 
GTP-bound a subunit then leads to the breaking of its linkages with the py subunit 
and the 7TM receptor. The dissociation of the a subunit and py subunit from the 
7TM receptor then allows regulation of intracellular signaling pathways (Gilman, 
1987). The 7TM receptor stays active while the agonist binds to it and therefore, it 
can catalyze the activation of many G proteins. 
Both activated a subunit and py subunits regulate the activity of the target proteins, 
depending on the types of G protein they belong to. There are many different kinds 
of Ga protein subtypes and those that are related to the generation of pain signals 
include Gs, Gi /�and Gq/n proteins. Gs protein activates adenylyl cyclase, which 
increases the conversion of ATP to cAMP (Simon et al., 1980)，whereas Gi/�protein 
inhibits adenylyl cyclase activity to decrease the conversion of ATP to cAMP 
(Wettschureck et al, 2005). Gq/n protein activates phospholipase C-beta (PLC-P) 
71 
which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl glycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3). IP3 triggers the release of intracellular 
calcium ions that activates protein kinase C (PKC) (Julius et al., 2001). Activation of 
PKC is involved in the pain signaling pathway (Hucho et al, 2005) as PKC-
knockout mice exhibit reduced thermal and mechanical hypersensitivity after 
treatment with adrenaline or acetic acid (Khasar et al, 1999a). 
I 
5.1.2 cAMP/PKA-mediated hyperalgesia 
In the DRG, agents that stimulate the production of cAMP tend to facilitate pain 
through a process called peripheral sensitization (see Section 1.2). Hyperalgesic 
agents such as prostanoids, including PGE2 and PGI2, bind to Gs-coupled GPCRs, 
leading to the dissociation of the Gs protein, which then activates the adenylyl 
cyclase for the conversion of ATP to cAMP (Simon et al, 1980). The cAMP is the 
secondary messenger that initiates peripheral hyperalgesia by activating the protein 
kinase A (PKA) pathway (Aley et al, 1999). The exact mechanism of cAMP/PKA-
mediated hyperalgesia is not fully understood, but studies revealed that it involves 
the modulation of voltage-gated Ca^^ channels and ligand-gated ion channels (Bhave 
et al, 2002; Fitzgerald et al., 1999). Alteration of these channels induces 
depolarization of sensory neurons and lowers the threshold for generating an action 
potential (Bley et al., 1998). This sensitizes the neurons and favors repetitive firing 
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of nociceptive signals by sensory neurons. Increased sensitivity to pain then occurs 
(Julius et a/., 2001). 
In contrast, analgesic agents such as opiates and cannabinoids alleviate pain by 
counteracting the changes resulting from the action of hyperalgesic agents. These 
analgesic agents couple to Gj/o-GPCRs, leading to the dissociation of the Gi/o protein 
that inhibits adenylyl cyclase. The decrease in cAMP production results in the 
restoration of the decreased threshold to generate nociceptive signals and therefore 
decreases pain signaling. 
5.1.2 Pharmacological characterization of prostanoid receptors on DRG cells 
Pharmacological characterization of functional expression of GPCRs involves the 
use of receptor-specific agonists and antagonists. The agonist should possess high 
affinity for the target receptors (Hoyer et al., 1994) and produce measurable 
responses such as the production of cAMP. To confirm that the agonist-stimulated 
responses are mediated through the target receptor, the antagonist, on the other hand, 
should demonstrate the ability to abolish the agonist-stimulated responses by 
blocking the target receptors (Hoyer et al., 1994). The concentrations of agonist and 
antagonist should be precisely chosen so that the agonist concentration will be 
adequate to activate the target receptors but not too high for the agonist to lose 
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selectivity for the target receptors, while the antagonist concentration will just be 
sufficient enough to block all agonist binding to abolish the agonist-stimulated 
responses. 
Our previous study provided evidence for the presence of pain-related prostanoid 
receptors (EP4 and IP receptors) on both DRG neurons and glial cells in vitro by 
using pharmacological tools (Ng et al” 2011). PGE2 (EP receptor agonist), ONO-
AEl-329 (EP4 receptor agonist) and cicaprost (IP receptor agonist) stimulated cAMP 
production in DRG cells. The PGE2- and ONO-AEl -329-stimulated responses were 
only inhibited by EP4 receptor antagonist ONO-AE3-208 (100 nM), while cicaprost-
stimulated responses were only inhibited by the IP receptor antagonist RO1138452 
(100 nM). These results demonstrated that PGE2 and ONO-AEl-329 mediated their 
responses via EP4 receptors, while cicaprost mediated its responses via IP receptors. 
Interestingly, glial cells responded well to both cicaprost and PGE2, while only small 
cicaprost- and PGEi-stimulated responses could be seen in neuron-enriched cells. 
Moreover, with approximately the same number of glial cells in mixed DRG cell 
cultures and glial cell cultures, the cicaprost-stimulated responses in glial cultures 
were significantly larger than those in the mixed DRG cultures; PGE2-stimulated 
responses also showed a similar pattern. 
74 
The smaller agonist-stimulated responses in mixed DRG cells suggested that the 
presence of neurons in the mixed DRG cells inhibited the cicaprost- and PGE2-
stimulated responses of glial cells. Further investigations were carried out to 
selectively label glial cells with [^ H] adenine and then to measure the responses of 
glial cells in the presence of unlabeled neurons that mimic the environment of mixed 
DRG cells. It was seen that the glial cells alone produced most of the cicaprost- and 
PGE2-stimulated responses compared to the glial cells with the addition of neurons. 
The result clearly demonstrated that the presence of neurons in mixed DRG cell 
cultures inhibited the cicaprost- and PGEi-stimulated responses in glial cells (Ng et 
al, manuscript in preparation). As a consequence of this data, we wanted to 
determine if similar relationships between DRG neurons and glial cells were seen 
with other GPCRs implicated in the regulation of pain. 
5.1.3 Gs- and Gi/o-coupled GPCRs in DRG cells 
Many GPCRs are found on the surface of DRG cells, including neurons and non-
neuronal cells. These GPCRs are responsible for mediating the release of 
neurotransmitters, neuropeptides and sensitizing neurons to facilitate pain, and 
desensitizing neurons to alleviate pain. Among all the GPCRs expressed on the DRG 
cells, we selected some Gs-coupled and Gj/o-coupled GPCRs that are clearly 
associated with pain for characterization. Discussed in the following sections are the 
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pain-related Gg- and Gj/o-coupled GPCRs chosen for this study. The agonists and 
antagonists used for GPCR characterization are listed in Table 5.1. 
5.1.3.1 Gs-coupled GPCR: p-adrenoceptors 
The adrenoceptors (ARs) are classified into two groups, a-ARs and p-ARs, based on 
physiological, pharmacological and molecular cloning experiments (Bond et al, 
1988; Bylund, 1985; Bylund, 1988). The adrenoceptors mediate various central and 
peripheral actions through the binding of endogenous sympathetic catecholamines, 
including adrenaline and noradrenaline. Adrenaline acts equally on both a-ARs and 
P-ARs, while noradrenaline acts preferentially on a-ARs (Bylund et al, 1994). 
There are three p-ARs subtypes, namely Pi-, p2- and Ps-ARs. They are predominantly 
expressed in different tissues for diverse functions, pi-ARs are the dominant 
receptors in heart and adipose tissue; P2-ARS are expressed on, but not limited to, 
neurons, vascular, uterine, and bronchial smooth muscle cells (Bylund et al., 1994; 
Nagatomo et aL, 2000). Ps-ARs are expressed on adipose tissue, stomach, liver, 
gastrointestinal tract, smooth and skeletal muscles (Bylund et al., 1994; Evans et al, 
1999; Leon et al., 2008). Regardless of the p-AR subtypes, P-ARs, which belong to 
< 
class A GPCR, are primarily coupled to Gs proteins, which stimulate adenylyl 
cyclase activity for the increase of intracellular cAMP level and leads to different 
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physiological responses (Bylund et al., 1994). Activation of Pi-ARs primarily 
mediates an increase in heart rate and contractile force, the relaxation of coronary 
arteries and gastrointestinal smooth muscles (Bylund et al, 1994); activation of p2-
and p3-ARs primarily mediate the relaxation of smooth muscle cells of peripheral 
tissues (Bylund et al, 1994; Evans et al., 1999). 
The presence of Pi- and Pz-AR mRNA and the absence of P3-AR mRNA has been 
reported in cultures of rat DRG cells (Leon et al, 2008). Without identifying the 
specific subtypes, P-AR-mediated responses have been reported in DRG neurons in 
vitro (Khasar et al., 1999b; Pluteanu et al, 2002) and in vivo (Khasar et al, 1999b). 
The direct evidence for the presence of p-ARs on DRG SGCs is not available in vivo, 
but the presence of P-ARs has been suggested (Hanani, 2010) to mediate the 
increased cAMP stimulated by isoprenaline (P1/P2-AR agonist) in SGCs of superior 
cervical sympathetic ganglia in vitro (Ariano et al., 1982). We have previously 
shown that isolated DRG cells from adult rats responded to isoprenaline and 
salbutamol (pi/p2-AR and P2-AR agonist) with an increase of cAMP production 
(Rowlands et al, 2001). 
The major distinction between the subtypes of p-ARs is their relative affinity to their 
endogenous ligands, adrenaline and noradrenaline (Bylund et al., 1994; Nagatomo et 
al., 2000). The pi-ARs have equal affinity for noradrenaline and adrenaline, whereas 
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P2-ARs have a 100-fold higher affinity for adrenaline than noradrenaline (Bylund et 
al, 1994; Nagatomo et al, 2000). In contrast, p3-ARs have a higher affinity to 
noradrenaline than adrenaline (Bylund et al, 1994). While there are many potent and 
selective p2-AR agonists that allow the characterization of the P2-ARS, the Pi-AR 
specific agonists are currently scarce. Among the few Pi-AR agonists, T-0509 is 
shown to be ppAR specific (Longhurst et al., 1999; Sato et al., 1996), but it is 
currently unavailable commercially. Pharmacological characterizations of the Pi-ARs 
are based on the studies that have used non-selective P1/P2-AR agonist, isoprenaline, 
to increase cAMP production (Jung et al., 1997; Pluteanu et al, 2002), and those that 
have used highly selective Pi-AR antagonists, such as atenolol at 10 |aM, to block the 
isoprenaline-stimulated responses (Morioka et al., 2009). Isoprenaline has a Ki value 
of 14 nM and 21 nM for rat Pi-ARs for P2-AR, respectively (Naito et al, 1985), 
while atenolol displays selectivity for Pi-ARs over p2-ARs with Kj values 125 nM 
and 1250 nM, respectively (Bylund et al, 1994). Specific agonists for P2-ARS 
include formoterol (Yalcin et al, 2010) while ICI 118551 is commonly used as the 
p2-AR specific antagonist (Bylund et al., 1994; Morioka et al, 2009; Yalcin et al., 
2010). Formoterol has a Ki value of 1:6 nM for P2-AR (Yalcin et al, 2010) and 
another study reported that formoterol displays 89-fold more selectivity for p2-ARs 
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than Pi-ARs (Kurose et al., 1998). The antagonist for p2-ARs，ICI 118551, has a Ki 
value of 4.6 nM for Pz-ARs and 710 nM for Pi-ARs (Bylund et al., 1994). 
In this study, the concentrations of isoprenaline (pi/p2-AR agonist) and formoterol 
(p2-AR agonist) were both 1 jjM, so that isoprenaline would be sufficient to activate 
both the p-ARs, while formoterol would only be selective for p2-ARs. Atenolol (pi-
AR antagonist) was chosen at 1 liM and ICI 118551 (p2-AR antagonist) was chosen 
at 100 nM, so that the antagonists would be sufficient to block all the Pi-AR and P2-
AR responses, respectively. 
5.1.3.2 Gs-coupled GPCR: C G R P receptors 
CGRP, a well-known hyperalgesic agent, is a 37-amino acid vasodilatory 
neuropeptide that is strongly associated with migraine (Doods et al., 2007; Walker et 
al, 2010). A direct role of CGRP in migraine can be simply revealed by the 
elevation of migraine-like headache after the peripheral injection of CGRP (Lassen et 
al, 2002; Zhang et al, 2007b). CGRP is released from the activated trigeminal 
ganglia (TG) nerves, and causes vasodilation of cerebral and dural vessels, which 
then leads to the transmission of pain signals from intracranial vessels to the CNS 
(Durham, 2004). Other than migraine, CGRP has also been found to relate to 
inflammation, allodynia and other diseases, such as rhinosinusitis (Vause et al, 2010) 
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and cardiovascular disease (Walker et al, 2010). CGRP is widely distributed in the 
CNS and PNS and is a very abundant peptide in nervous tissue (Li et al., 2008). 
Around 50% of the small- and medium-diameter peptidergic neurons in the DRG 
synthesize and release CGRP from nerve endings (Segond von Banchet et al.，2002). 
Moreover, CGRP has also been found to be released from the cell bodies of 
trigeminal neurons in the TG, which affects (1) neighboring neurons in an autocrine 
manner and (2) the associated glial cells in a paracrine manner (Thalakoti et al., 2007; 
Vause et a/., 2010). 
CGRP stimulates CGRP receptors, which are heterodimers formed between a class B 
GPCR, named calcitonin receptor-like receptor (CLR)，and a transmembrane protein, 
named receptor activity-modifying protein (RAMP) 1 (Lennerz et al, 2008; Li et al., 
2008; Vause et al., 2010; Zhang et al., 2007a). For proper receptor function, an 
additional protein called receptor component protein (RCP) is also required (Walker 
et al., 2010). CGRP receptors couple mainly to Gs proteins, but they can also couple 
to Gi/o proteins (Disa et al, 2000; Walker et al, 2010) and Gq/n proteins (Drissi et al, 
1998; Morara et a!., 2008; Walker et al, 2010). Historically, two isoforms of CGRP 
receptor, CGRPi and CGRP2, have been described (Moreno et al., 2002; Segond von 
Banchet et al, 2002). However, whether CGRP2 exists is still in doubt. It is 
suggested that CGRP2 receptor might actually be the result of CGRP binding to 
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human adrenomedullin (AMi and AM2) receptors, which are both structurally similar 
to CGRP receptors but are composed of different RAMP isoforms (Hay et al., 2004; 
Walker et «/.,2010). 
Although CGRP receptors have been studied extensively in TG for their strong 
association with headache, CGRP receptors are also shown to be expressed on DRG 
neurons in vivo and in vitro (Ceruti et al, 2011; Segond von Banchet et al., 2002; Ye 
et al, 1999). It has also been suggested that the activation of CGRP receptors 
sensitizes neighboring neurons for the release of mediator (Segond von Banchet et al., 
2002). CGRP receptors are also reported to be present on SGCs in TG both in vivo 
and in vitro (Ceruti et al, 2011; Eftekhari et al, 2010), suggesting a role of glial cells 
in migraine pathology (Ceruti et al, 2011). 
CGRP is a potent agonist for CGRP receptors. A study characterizing CGRP receptor 
subtypes in COS-7 cells transfected with CLR and RAMPs indicated that rat CGRP 
had affinity for CGRP receptors (EC50： 0.86 nM) as well as AMi (EC50： 147 nM) and 
AM2 (EC50： 59 nM) receptors (Husmann et al, 2000). CGRP antagonists are 
relatively scarce. CGRPg-s? and BIBN4096BS are the two antagonists for CGRP 
(Doods et al, 2000), but BIBN4096BS is currently commercial unavailable. CGRPg. 
37，a truncated form of CGRP, is an antagonist (Chiba et al., 1989), with CGRPs-s? 
(10 ^M) inhibiting almost 100% of the CGRP-stimulated cAMP production in 
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human neuroblastoma cell lines (Doods et al., 2000). In our previous study, CGRP 
was used at 1 |aM in order to produce responses which were similar to that stimulated 
by cicaprost and PGE2 in mixed DRG cells (Rowlands et al, 2001). Therefore, 1 |iM 
CGRP was also used in this current study, and 10 pM CGRPg-s? was used to inhibit 
the CGRP-stimulated cAMP production. 
5.1.3.3 Gi/o-coupled GPCR: a2-adrenoceptors 
Pharmacological and biochemical studies on the a-ARs have accumulated that 
indicate the heterogeneities of distinct but related a-ARs, which are the ai- and 012-
ARs (Bylund et al., 1994; Graham et al, 1996; Minneman et al., 1994). The ai-ARs 
predominantly couple to Gq/n proteins while the az-ARs couple to Gi proteins 
(Summers et al, 1993). While activation of both ai-ARs and 0x2-ARs lead to the 
contraction of smooth muscles, activation of neuronal a2-ARs has been suggested to 
relate to pain (Hein, 2006). 
The a2-ARs are found in brain, blood platelets, vascular smooth muscles, skeletal 
muscles and nerve endings (Bylund et al, 1994; Lorenz et al, 1990). The subtypes 
of ai-ARs (a2A-AR, azs-AR and azc-AR) were characterized by the different affinity 
I 
for prazosin, an ai/a2-AR antagonist (Lorenz et al, 1990). The a2A-AR had low 
affinity for prazosin and was found in the platelet (Bylund et al, 1994; Lorenz et al., 
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1990). The a2B-AR, showing at least 30-fold higher affinity for prazosin than aiA-AR, 
was characterized in neonatal rat lung. The azc-AR showed similar affinity for 
prazosin and was found in opossum kidney tissue (Bylund et al., 1994). Activation of 
the 012-ARs have been found to mediate functions such as reduction in blood pressure, 
and sedation and inhibition of fluid secretion, and produce an analgesic effect (Maze 
et aL, 1991). 
The presence of a2-ARs on DRG neurons has been reported in vivo (Shi et al., 2000) 
in both normal and nerve injured rat model (Cho et al, 1997; Gold et al, 1997; 
Supowit et al, 1998). In some in situ hybridization studies, a2c-AR mRNAs were 
shown to be present in the DRG neurons (Ma et al, 2005; Nicholson et al., 2005). 
The a2A-AR expression was found to be up-regulated in DRG neurons following 
neuropathy and responded to noradrenaline that was released by the nearby 
sympathetic efferent nerve fibers (Shi et al, 2000). This suggested the role of a2-ARs 
in influencing nociception and pain processing (Yalcin et al, 2010). However, the 
expression of a2-ARs has not been investigated in DRG glial cells. 
The activation of az-ARs mediates signaling pathways via both Gu and Gpy subunits. 
The a2-ARs couple to Gaj and the activation of the inhibitory Gai protein inhibits the 
adenylyl cyclase activity, thus resulting in decreased cellular cAMP levels. Moreover, 
the Gpy subunit regulates neuronal function by inhibiting neuronal Ca^^ channels and 
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activating GIRK K+ channels and mitogen-activated (MAP) kinases ERK1/2 (Hein, 
2006). The consequences of the activation of the a2-ARs include suppression of the 
entry of Ca^ ,^ hyperpolarization of the sensory neurons, inhibition of nerve impulse 
firings, a decrease in neurotransmitter release and hence, resulting in the production 
of an analgesic effect (Maze et al, 1991). However, there has been opposite evidence 
that os-ARs play an important role in generating sympathetically maintained 
neuropathic pain (Cho et al, 1997). 
Selective agonists for a2-ARs include clonidine and UK14304, while selective 
antagonists include yohimbine (Bylund et al., 1994). To characterize the ai-ARs, 
UK14304 is preferred over clonidine because UK14304 acts as a full agonist while 
clonidine acts as a partial agonist for the a2-ARs (Maze et al., 1991). UK14304 has a 
Ki value of 2.4 nM for 012-ARs and 1900 nM for ai-ARs (Munk et al, 1995). In this 
study, the concentration of UK14304 was chosen at 1 |iM so that the concentration is 
sufficient to activate az-ARs but is not too high to lose the selectivity. The antagonist, 
yohimbine, has a KD value of 100 nM for 012-ARs (Pushpendran et al., 1984) and 1 
|iM was chosen so that the concentration of the antagonist would be high enough to 
block any a2-AR responses. 
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5.1.3.4 Gi/o-coupled GPCR: Cannabinoid receptors 
Cannabinoid (CB) receptors are known for their roles in mediating the actions of the 
cannabinoid drugs that were isolated and identified from a plant species Cannabis 
sativa, including marihuana, hashish, and bhang (Gaoni et al., 1964). Currently, there 
are two CB receptors being described, which are the cannabinoid receptor 1 and 2 
(CBl and CB2). CBl and CB2 share 44% of the amino acid sequence and differ in 
their tissue distributions (Howlett et al, 2002). One of the most well-known effect of 
cannabinoid receptor-mediated action is analgesia (Howlett, 1995). The CB receptors 
are classified as Class A GPCRs that couple to Gi/�proteins to inhibit adenylyl 
cyclase activity (Foord et al” 2005; Pertwee, 1997). CBl receptors are found 
predominantly at central and peripheral nerve terminals mediating inhibition of 
neurotransmitter release, while CB2 receptors are found predominantly on immune 
cells modulating cytokine releases (Pertwee, 2005). Having responsibility for 
producing analgesic effects, it is not a surprise that CB receptors are found in DRG. 
The CBl receptors have been well-characterized for their expression in DRG 
neurons in situ, and in vitro (Ahluwalia et al, 2000; Bridges et al., 2003; Fischbach 
et al., 2007), however, expression of CBl receptors on glial cells is not known. 
4 
Other than immune cells, the expression of CB2 receptors has recently been 
suggested on DRG neurons both in vivo and in vitro (Hsieh et al, 2011; Sagar et al.’ 
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2005). Other study has shown that CB2 receptors were found on activated microglial 
cells, which are the immune-like cells in the CNS (Zhang et al., 2003) but expression 
of CB2 receptors on DRG glial cells is not known. 
The main psychoactive component of cannabis is A9-tetrahydrocannabinol (A9-
THCl). It is responsible for the CNS effects, such as sedation, and PNS effect such 
as analgesia (Hewlett et al, 2002). There are endogenous CB receptor ligands which 
are referred as endocannabinoids, including eicosanoids such as 
arachidonylethanolamide, also known as anandamide, and 2-arachidonoylglycerol, 
also known as noladin ether (Howlett et al, 2002; Smith et al, 1994; Sugiura et al., 
1995). Synthetic CB receptor agonists include CP55940, R-(+)-WIN55212 and the 
A9-THC1 analog, HU-210. Although these agonists have different potencies towards 
the CB receptors, they display no remarkable selectivity for the subtypes of the CB 
receptors (Howlett et al, 2002). The development of CB receptor-specific agonists 
was based on the structural modification of anandamide. Methanandamide is the first 
generation of CBl selective agonist modified from anandamide (Howlett et al, 2002; 
Khanolkar et al., 1996). Being a molecule that contains a chiral center, the isomers of 
methanandamide display different affinities for the CBl receptor. It is reported that 
the R-(+)-methanandamide has nine-fold higher affinity than the R-(-)-
methanandamide for the CBl receptors (Abadji et al, 1994). R-(+)-methanandamide 
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has a Ki value of 20 nM and 815 nM for CBl (rat brain) and CB2 (mouse spleen) 
receptors, respectively (Khanolkar et ah, 1996). To selectively activate CBl 
receptors, the agonist R-(+)-methanandamide was chosen at 100 nM so that at this 
concentration, only CBl but not CB2 will be activated. The CBl antagonist, AM251, 
has a Ki value of 7.49 nM and 2290 nM for CBl (rat brain) and CB2 (mouse spleen) 
receptors (Lan et al., 1999). Being a 306-fold more selective for the blockade of CBl 
than CB2, AM251 was initially chosen at 1 fiM so that it was sufficient but selective 
to inhibit CBl-induced inhibition of adenylyl cyclase activity. The concentration was 
later increased to 10 |aM ensuing sufficient blocking of CBl receptor by the 
antagonist. 
For CB2 receptors, L759656 was shown to be highly selective, displaying Ki values 
of 11.8 nM and 4888 nM for human CB2 and CBl receptors in transfected CHO 
cells, respectively (Huffman, 2000). The concentration chosen for L759656, 1 \iM, 
would selectively activate CB2 receptors. The antagonist AM630 was shown to 
specifically inhibit CB2 receptors, displaying Ki values of 31.2 nM and 5152 nM for 
human CB2 and CBl receptors, as determined from CBl and CB2 receptor-
transfected CHO cells (Ross et al., 1999). The concentration chosen initially for 
AM630 was 1 i^M that was sufficient to selectively abolish CB2-induced inhibition 
of adenylyl cyclase activity. This concentration was later increased to 10 |iM to 
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ensure sufficient blocking of the CB2 receptor by the antagonist. The use of AM630 
at 10 |LIM has also been shown to reverse anandamide-induced inhibition on 
neurotransmitter releases and Ca^^ mobilization of dissociated rat DRG cells 
(Tognetto et a/., 2001). 
5.1.3.5 Gi/o-coupled GPCR: 5-HTIA receptors 
The serotonin 1A (5-HTIA) receptor belongs to a subtype of the 5-HT receptor family. 
This receptor subtype is classified as a Class A GPCR that couples mainly to Gi/� 
protein which, when activated, inhibits the activity of the adenylyl cyclase and leads 
to the reduction of cAMP production (Foord et al., 2005; Hoyer et al, 2002). The 5-
HTIA receptors are found within both the central and peripheral tissues including 
DRG neurons (Nicholson et al., 2003). 
In the CNS, 5-HTIA receptors are expressed at high density in rat hippocampus. 5-
HT is a neurotransmitter released by the brainstem structures that play an important 
role in sensory information processing, which is found to be 5-HTIA receptor-
mediated (Liu et al, 2002; Nicholson et al., 2003). In the PNS, a majority of 5-HTIA 
receptors can be found in mast cells and platelets. The endogenous ligand, 5-HT, is 
released as an inflammatory agent and it activates the 5-HTIA receptors to influence 
physiological effects. One of the consequences of 5-HTIA receptor activation is 
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analgesia. 5-HTIA receptor mRNA has been shown in whole DRG and the mRNA 
expression of this receptor increased after during inflammatory pain condition (Liu et 
al, 2005). The presence of 5-HTIA receptors on DRG neurons is supported by 
electrophysiological study that revealed expression of 5-HTIA receptors on C-fiber of 
DRG neurons and activation of 5-HTIA mediated hyperpolarization of the capsaicin-
sensitive C-fiber (Todorovic et al, 1992). Hyperpolarization of C-fiber reduces pain 
signals and hence alleviates pain sensation. However, expression of 5-HTIA in DRG 
glial cells has not been reported. 
To characterize the 5-HTIA receptor, 8-OH-DPAT has been commonly used as a 
receptor-specific agonist for 5-HTIA receptors (Newman-Tancredi et al., 1998a; 
Todorovic et al., 1992). The KI value of 8-OH-DPAT is 0.58 nM for human 5-HTIA 
receptors transfected in CHO cells (Newman-Tancredi et al., 1998a). The 
concentration of 8-OH-DPAT used in this study was 1 |LIM, which should activate 
majority 5-HTIA receptors. S-WAY100135 is a potent and selective 5-HTIA receptor 
antagonist which has a KI value of 10.3 nM for human 5HTIA receptors transfected in 
CHO cells (Newman-Tancredi et al., 1998b). The concentration of S-WAY 1001135 
was used at 500 nM in this study. 
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5.1.3.6 Gi/o-coupled GPCR: opioid and opioid-receptor-like 1 receptors 
The opioid receptors (ORs) are another family of receptors well-known for mediating 
analgesic effects. There are currently three ORs, namely |I-OR, 5-OR, and K-OR, 
and a opioid-receptor-like receptor, namely opioid-receptor-like 1 (ORLl) receptor 
(Fichna et al., 2007). They all belong to Class A GPCRs and couple to Gi/�proteins. 
These receptors are found in many tissues in the CNS and PNS for the mediation of 
analgesic effects. In the brain, opioid receptors are found to be expressed at high 
densities in the regions that integrate information about pain, such as the brainstem, 
the medial thalamus and the hypothalamus (Fichna et al., 2007). In the spinal cord, 
opioid receptors are located at both presynaptic terminals of the primary sensory 
neurons and post-synaptic nerve terminals of the dorsal horn of the spinal cord. In the 
PNS, the opioid receptors are also expressed in the DRG, immune cells and 
subcutaneous tissues (Stein et al, 2009). Currently, the presence of |i-ORs on glial 
cells both in vivo and in vitro has not been reported. In the DRG, the |x-ORs have 
been found to be the most predominant opioid receptor subtype to be expressed 
under normal conditions (Ji et al, 1995) and to be up-regulated during inflammation 
(Ji et al., 1995; Puehler et al, 2004). Within all the DRG neurons, ^i-ORs were 
i 
shown to be expressed on small diameter neurons that are nociceptive neurons 
containing hyperalgesic neuropeptides, such as CGRP and substance P (Levine et al., 
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1993; Li et al., 1998). These studies revealed a more important role of [x-OR than 5-
OR and K-OR in modulating nociception. With a vast amount of studies on |i-OR in 
modulating nociception, we begin studying the expression of opioid receptors on 
DRG cells by characterizing the |x-OR. 
The signaling pathway of |x-OR activation is well-documented. The activated Gui/� 
protein dissociated from activated |i-OR inhibits adenylyl cyclase activities that 
abolish the activation of PKA signaling pathway leading to hyperpolarization of the 
small diameter neurons. The activated Py subunit, on the other hand, inhibit the 
voltage-gated Ca^ "^  channels and the activation of the K+ channels that hyperpolarize 
the neurons to reduce the generation of pain signals (Cunha et al, 2010). As a 
consequence, the excitability of neurons is decreased, attenuating the generation of 
pain signals and the release of hyperalgesic agents such as substance P and CGRP 
and therefore, an anti-nociceptive effect occurs (Stein et al., 2009). In addition to the 
Gai/o, the Gpy subunit has been suggested to alleviate hypemociception by activating 
PI3Ky, a member of the PI3K enzyme family. This leads to the activation of a 
PI3K/AKT signaling pathway that stimulates production of nitric oxide (NO) and 
consequently, NO promotes hyperpolarization of nociceptive neurons by indirectly 
activating KATP channel to reduce pain signal generation (Cunha et al., 2010). Taken 
together, opioid receptors have important roles in the controlling pain. 
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Potent agonists for the ji-OR includes morphine and DAMGO, but DAMGO displays 
higher selective for the ^i-OR over the other receptor subtypes. DAMGO has a Kj 
value of 2.0 nM and 1200 nM for rat ^I-ORs and K-ORS, respectively (Meng et al., 
1993; Raynor et al., 1994). For |i-OR antagonist, naloxone is preferably used 
displaying pA! value of 8.6 for |x-ORs (Mulder et al, 1991). For the characterization 
of |i-ORs, 1 \xM of DAMGO and naloxone were used to specifically activate and 
inhibit |i-ORs, respectively, in the DRG cells. 
The ORLl receptors share many characteristics with the opioid receptors, including 
amino sequence homology, G-protein coupling and the association with pain 
processing (Henderson et al., 1997). It has been shown that the mRNA expression of 
ORLl receptors was mainly on small diameter and medium diameter neurons which 
are the DRG neurons that are responsible for nociception (Chen et al., 2006). 
However, expression of ORLl receptors on DRG glial cells is not reported. 
Moreover, the mRNA expression of ORLl receptors has been shown to be increased 
during inflammation and nerve injury (Chen et al., 2006). ORLl receptors are 
coupled to Gj/o protein to inhibit adenylyl cyclase activity, and to the inhibition of 
voltage-gated Ca^^ channels and the activation of the K+ channels that hyperpolarize 
the neurons to reduce the generation of pain signals and inhibit the release of 
hyperalgesic agents such as substance P and CGRP (Henderson et al., 1997; Mika et 
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al, 2003). Nociceptin is used as a potent ORLl receptor agonist with Kj value of 0.4 
nM, which has no significant activity at the opioid receptor subtypes (Dooley et al., 
1997; Henderson et al, 1997). Antagonists for ORLl receptors include J11397 
which has Ki values of 1.8 nM, 1000 nM, >10000 nM, and 640 nM for human ORLl 
receptors ^i-OR, 5-OR and K-OR, respectively (Pol et al, 2004). For the 
characterization of ORLl receptors, 1 joM of N/OFQ was chosen to activate ORLl 
receptors, while 300 nM J11397 was chosen to inhibit the receptor activation by the 
agonist. 
5.2 Aims of study 
We have previously shown that prostanoid receptors (EP4 and IP receptors) were 
expressed on both DRG neurons and glial cells in dissociated cells cultures. These 
prostanoid-stimulated responses in glial cells were inhibited by the presence of 
neurons. The expression of pain-related receptors on glial cells suggests that glial 
cells possess the ability to respond to hyperalgesic agents. The characterization of 
pain-related receptors on glial cells may reveal a novel role of glial cells in the 
development and maintenance of hyperalgesia and the interaction with neurons. As a 
preliminary investigation, this study aimed to investigate if the pronociceptive-
related Gs-coupled and anti-nociceptive Gi/�-coupled GPCRs were expressed on 
DRG neurons and glial cells in cultures. By using pharmacological tools, we 
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measured cell responses, i.e. the production of [^H]cAMP in mixed DRG cells, 
neuron-enriched cells and glial cells upon agonist and antagonist incubation. Besides, 
we also investigated the effect of neurons in influencing the agonist-stimulated 
responses in glial cells. 
5.3 Results 
5.3.1 Characterization of prostanoid receptors in isolated DRG cells 
The adenylyl cyclase activity was determined in mixed DRG, neuron-enriched, and 
glial cells by measuring the percent conversion of [^H]ATP to [^H]cAMP following 
agonist and/or antagonist treatments. Cicaprost and PGE2 were the agonists used to 
stimulate the prostanoid receptors in the three DRG cell cultures. We have previously 
demonstrated that cicaprost and PGE2 stimulated the production of [^H]cAMP in the 
three DRG cell cultures. Besides, the cicaprost- and PGE2-stimulated responses 
could only be antagonized by the IP receptor-specific antagonist, ROl 138452, and 
EP4 receptor-specific antagonist, ONO-AE3-208, respectively. The results indicated 
that cicaprost mediated its response via IP receptors and PGE2 mediated its response 
via EP4 receptors. The pECso values for cicaprost and PGE2 were 7.38 土 0.06 and 
I 
6.86 土 0.19，respectively, in mixed DRG cells (Ng et al, 2011). As a result, the 
concentration used in this study to stimulate [^H]cAMP production was chosen at 40 
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nM for cicaprost, which was the EC50 value determined in DRG cell cultures, 
whereas the concentration for PGE2 was chosen at 1 jxM, which was the 
concentration that would produce nearly the maximum responses so that the 
responses were comparable to the cicaprost-stimulated responses. Forskolin (1 |iM), 
a receptor-independent compound, was used to stimulate adenylyl cyclase activity 
directly to increase the production of [^H]cAMP without acting through a receptor. In 
this current study, cicaprost and forskolin stimulated adenylyl cyclase activity 
leading to the increase [^HjcAMP production in all three DRG cell cultures (Fig. 5.1). 
Cicaprost increased the fH]cAMP in mixed DRG cells {p < 0.001) and glial cells {p 
< 0.001) while the increase in ^HJcAMP was not shown to be significant in neuron-
enriched cell cultures (p > 0.05). Relative to the basal activities, the increase in 
response to cicaprost was 4.6-fold in mixed DRG cells, 1.9-fold in neuron-enriched 
cells, and 16.4-fold in glial cells. Forskolin significantly increased the [^H]cAMP in 
mixed DRG cells {p < 0.001), neuron-enriched cells {p < 0.001), and glial cells (p < 
0.01). Relative to the basal activities, the increase in response to forskolin was 9.5-
fold in mixed DRG cells, 5.4-fold in neuron-enriched cells, and 10.4-fold in glial 
cells. Regardless of the cicaprost and forskolin treatments, the stimulated responses 
t 
of neuron-enriched cells were smaller than that of the mixed DRG cells (p < 0.001). 
Comparing the cicaprost-simulated responses between mixed DRG cells and glial 
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cells, the responses produced in the mixed DRG cells were significantly smaller than 
that in the glial cells (p < 0.001). However, this inhibitory pattern was not seen in 
forskolin-stimulated responses. The mixed DRG cells produced larger forskolin-
stimulated responses when compared with the responses in glial cells (p < 0.001). 
5.3.2 Characterization of CGRP receptors in isolated DRG cells 
The CGRP receptors in the three DRG cell cultures were characterized by 
stimulation with the endogenous CGRP receptor agonist, CGRP (1 i^M), and by the 
blockade of the receptors with CGRP antagonist, CGRPg-s? (10 i^M) (Fig. 5.2). 
CGRP significantly increased the production of [^H]cAMP in mixed DRG cells (p < 
0.01) and glial cells (p < 0.001), while the increase in fH]cAMP was not shown to 
be significant in neuron-enriched cell cultures {p > 0.05). Relative to the basal 
activities, the increase in ^HJcAMP stimulated by CGRP was 5.1 士 1.0-fold in 
mixed DRG cells, 2.1 士 0.5-fold in neuron-enriched cells and 20.1 士 2.8-fold in glial 
cells. Pretreatment with CGRPg-s? alone had no effect on [^H]cAMP production {p > 
0.05) but inhibited CGRP-stimulated fH]cAMP production by 60 土 6o/o (p < 0.001) 
in mixed DRG cells, 40 土 15o/o in neuron-enriched cells (p < 0.01) and 39 士 3o/o (p < 
0.001) in glial cells. CGRP produced a similar response pattern compared with the 
responses produced by cicaprost in the three DRG cell cultures (Fig 5.3). Both 
CGRP-stimulated and cicaprost-stimulated responses in the mixed DRG cells were 
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significantly smaller than those in the glial cells {p < 0.001 and p < 0.01, 
respectively), but were significantly larger than those in the neuron-enriched cell (p < 
0.05 and p < 0.01, respectively). 
5.3.3 Investigation of the effect of CGRPs-a? on CGRP responses 
In Fig. 5.2, the CGRP-stimulated responses could only be partially inhibited by the 
antagonist, CGRPg-s? (10 |iM), suggesting that the concentration of agonist or 
antagonist might not be optimal. Therefore, log agonist concentration-response 
curves for CGRP in the presence of the CGRPg-s? were generated using mixed DRG 
cells (Fig. 5.4). The pECso values for CGRP alone and in the presence of CGRPg-s? 
were 7.40 士 0.25 and of 6.56 士 0.19，respectively (p < 0.05). In the presence of the 
CGRP8-37, the dose-response curve shifted to the right with a lower pECso value. 
CGRP8-37 significantly decreased both the basal activity and CGRP-stimulated 
responses at all the concentrations that were tested. The inhibition of CGRP-
stimulated responses by the CGRPg-av was clearly insurmountable. 
5.3.4 Characterization of pi-adrenoceptors in isolated DRG cells 
The Pi-ARs in the three DRG cell cultures were characterized by stimulation with a 
Pi/PZ-AR agonist, isoprenaline (1 |IM), and by the blockade with Pi-ARs specific 
antagonist, S-(-)-atenolol (1 |LIM) (Fig. 5.5). Isoprenaline significantly increased the 
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production of [^H]cAMP in mixed DRG cells, neuron-enriched cells and glial cells {p 
<0.001). Relative to the basal activities, the increase in [^H]cAMP was 3.5 土 0.5-fold 
in mixed DRG cells; 2.9 土 0.2-fold in neuron-enriched cells, and 3.3 土 0.2-fold in 
glial cells. Pretreatment with S-(-)-atenolol alone had no effect on [^H]cAMP 
production {p > 0.05) and showed no inhibition on the isoprenaline-stimulated 
[^H]cAMP production in all three DRG cell cultures (p > 0.05). Comparing the 
isoprenaline-simulated responses between mixed DRG and glial cell cultures, the 
responses in the mixed DRG cells were significantly larger than the responses in the 
neuron-enriched cells (p < 0.001) and glial cells (p < 0.01). 
5.3.5 Characterization of P2-adrenoceptors in isolated DRG cells 
The p2-ARs in the three DRG cell cultures were characterized by stimulation with a 
P2-AR specific agonist, formoterol (1 |iM), and by the blockade with P2-AR specific 
antagonist, ICI118551 (1 |LIM) (Fig. 5.6). Formoterol significantly increased the 
production of [^H]cAMP in mixed DRG cells, neuron-enriched cells and glial cells (p 
< 0.001). Relative to the basal activities, the increase in [^H]cAMP was 3.4 土 0.5-
fold in mixed DRG cells, 2.7 士 0.3-fold in neuron-enriched cells and 3.4 士 0.2-fold in 
glial cells. Pretreatment with ICI118551 alone had no effect on [^H]cAMP 
production (p > 0.05) but inhibited formoterol-stimulated [^H]cAMP production by 
77 士 2o/o (p < 0.001) in mixed DRG cells, 78 士 5o/o in neuron-enriched cells (p < 
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0.001) and 76 士 9o/o in glial cells {p < 0.001). Formoterol and isoprenaline produced 
a different response pattern compared with the responses produced by cicaprost in 
the three DRG cell cultures (Fig. 5.7) The formoterol and isoprenaline-simulated 
responses in the mixed DRG cells were similar to those in glial cells. In contrast, for 
cicaprost stimulations, mixed DRG cell responses were smaller than glial cells 
responses {p < 0.01) but larger than neuron-enriched cells (p < 0.05). 
5.3.6 Identification of p-adrenoceptor subtype mediating isoprenaline-
stimulated responses 
As shown in Fig. 5.5, there was a lack of inhibition on the isoprenaline-stimulated 
responses by the pi-AR specific antagonist, S-(-)-atenolol. Experiments were then 
performed to investigate if isoprenaline-stimulated responses were mediated through 
p2-ARs. To study this, the three DRG cells cultures were pretreated with Pi-AR 
specific antagonist, S-(-)-atenolol (1 |LIM), or P2-AR specific antagonist, ICI118551 
(100 nM) for 15 min before addition of pi/ P2-AR agonist, isoprenaline (1 |_iM) (Fig. 
5.8). Consistent with previous result, isoprenaline stimulated the increase in 
[^H]cAMP production in mixed DRG cells {p > 0.05)，neuron-enriched cells (p > 
0.01) and glial cells (p > 0.001). S-(-)-atenolol could not inhibit the isoprenaline-
stimulated [^H]cAMP production in any of the three cell cultures {p > 0.05), whereas 
ICIl 18551 inhibited isoprenaline-stimulated [^H]cAMP production by 100 士 10% in 
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mixed DRG cells (p < 0.001), 58 士 24o/o in neuron-enriched cells (p < 0.01) and 93 士 
l%in glial cells (p< 0.001). 
5.3.7 Characterization of a2-adrenceptors in isolated DRG cells 
The presence of Gj/o-coupled GPCRs is demonstrated when the presence of receptor-
specific agonist inhibits the forskolin-stimulated fHJcAMP production, while the 
presence of receptor-specific antagonist restores the agonist-inhibited forskolin 
responses. To characterize 012-AR, UK 14304 (1 [oM), an ai-AR specific agonist, was 
used to inhibit the forskolin-stimulated responses in the three DRG cell cultures (Fig. 
5.9), while yohimbine (1 |aM), an az-AR specific antagonist, was added 15 min 
before the addition of forskolin and UK14304. Treatment with UK143 04 had no 
effect on [^H]cAMP when treated alone and failed to inhibit on the forskolin-
stimulated [^H]cAMP production in all three DRG cell cultures. Pretreatment with 
yohimbine showed no effect on [^HJcAMP when pretreated alone in all three DRG 
cell cultures. Results indicated the absence of Gi/o/AC-coupled a2-AR in DRG cell 
cultures. 
5.3.8 Characterization of cannabinoid 1 receptors in isolated DRG cells 
( 
The CBl receptor agonist, R-(+)-methanandamide (100 nM), was used to inhibit the 
forskolin-stimulated responses in the three DRG cell cultures (Fig. 5.10), while 
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AM251 (10 laM), was added 15 min before the addition of forskolin and AM251. 
Treatment with R-(+)-methanandamide had no effect on [^H]cAMP when treated 
alone and failed to the forskolin-stimulated [^H]cAMP production in all three DRG 
cell cultures. Pretreatment with AM251 showed no effect on [^H]cAMP when 
pretreated alone in all three DRG cell cultures. Results indicated the absence of 
Gi/o/AC-coupled CBl receptor in DRG cell cultures. 
5.3.9 Characterization of cannabinoid 2 receptors in isolated DRG cells 
The CB2 receptor agonist, L759656 (1 |JM), was used to inhibit the forskolin-
stimulated responses in the three DRG cell cultures (Fig. 5.11), while AM630 (10 
|iM), a CB2 antagonist, was added 15 min before the addition of forskolin in and 
L759656. Treatment with L759656 had no effect on [^H]cAMP when treated alone 
and failed to inhibit the forskolin-stimulated [^H]cAMP production in all three DRG 
cell cultures. Pretreatment with AM640 showed no effect on [^H]cAMP when 
pretreated alone in all three DRG cell cultures. Results indicated the absence of 
Gi/o/AC-coupled CB2 receptors in DRG cell cultures. 
5.3.10 Characterization of 5-HTIA receptors in isolated D R G cells 
The 5-HTIA receptor agonist, 8 -OH-DPAT (1 pM), was used to inhibit the forskolin-
stimulated responses in the three DRG cell cultures (Fig. 5.12), while S-WAY100135 
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(500 |iM), was added 15 min before the addition of forskolin and 8-OH-DPAT. 
Treatment with 8-OH-DPAT had no effect on [^H]cAMP when treated alone and 
failed to inhibit the forskolin-stimulated fH]cAMP production in all three DRG cell 
cultures. Pretreatment with S-WAY100135 showed no effect on [^H]cAMP when 
pretreated alone in all three DRG cell cultures. Results indicated the absence of 
Gi/o/AC-coupled 5-HTIA receptors in DRG cell cultures. 
5.3.11 Characterization of 抖-opioid receptors in isolated DRG cells 
The \x-OR receptor agonist, D A M G O (1 |JM), was used to inhibit the forskolin-
stimulated responses in the three DRG cell cultures (Fig. 5.13), while naloxone (1 
jiM), a |i-OR receptor antagonist, was added 15 min before the addition of forskolin 
and DAMGO. Treatment with DAMGO had no effect on [^H]cAMP when treated 
alone and failed to inhibit the forskolin-stimulated fH]cAMP production in all three 
DRG cell cultures. Pretreatment with naloxone showed no effect on [^H]cAMP when 
pretreated alone in all three DRG cell cultures. Results indicated the absence of 
Gi/o/AC-coupled |a-OR receptors in DRG cell cultures. 
5.3.12 Characterization of opioid-receptor-like 1 receptors in isolated DRG 
cells 
The ORLl receptor agonist, N/OFQ (1 jjM), was used to inhibit the forskolin-
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stimulated responses in the three DRG cell cultures (Fig. 5.14), while J11397 (300 
nM), an ORLl receptor antagonist, was added 15 min before the addition of 
forskolin and N/OFQ. Treatment with N/OFQ had no effect on [^H]cAMP when 
treated alone and failed to inhibit the forskolin-stimulated [^H]cAMP production in 
all three DRG cell cultures. Pretreatment with J11397 showed no effect on 
[^H]cAMP when pretreated alone all three DRG cell cultures. Results indicated the 
absence of Gj/o/AC-coupled ORLl receptors in DRG cell cultures.. 
5.3.13 Effect of nerve growth factor on DRG cells 
For all the agonists that coupled to Gs proteins being tested in this study, neuron-
enriched cells produced responses that were significantly smaller than those of the 
mixed DRG cells which was unexpected. This small response could be due to the 
decrease of receptor expression in the first two days in cultures and the lack of 
neurotropic factors (Franklin et al., 2009)，which could be provided by glial cells 
(Zhou et al., 1999). Neurotropic factors such as NGF are essential for survival of 
DRG neurons during embryonic development but not in adult DRG neurons (Lindsay, 
1988). However, it has been suggested that addition of NGF could facilitate the re-
expression of receptors of adult nociceptive DRG neurons in isolated cultures 
(Franklin et al., 2009). We therefore hypothesized that addition of NGF would help 
enhance the neuron-enriched cell responses to Gs agonists. We have previously 
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demonstrated that NGF (50 ng/ml) had no effect on the Gs agonist-stimulated 
responses in mixed DRG cells (Wise, 2006) but the same has not been tested on 
neuron-enriched cells and glial cells. As a result, the effect of NGF on Gs-stimulated 
responses was tested in mixed DRG cells, neuron-enriched cells and glial cells (Fig 
5.15A-C). Mixed DRG cells were incubated with NGF (50 ng/ml) for 48 h, while 
neuron-enriched cells and glial cells were incubated with NGF for 24 h before 
assaying the adenylyl cyclase activity. On the assay day, cells were incubated with 
control solution (basal), receptor-independent adenylyl cyclase activator, forskolin (1 
|LIM), and GS agonists including IP receptor agonist (cicaprost, 40 nM), EP4 agonists 
(ONO-AEl-329, 1 ^M; PGE2, 1 |iM) an d P2-AR agonist (formoterol, 1 \M). 
Production of [^H]cAMP in response to Gs agonist-stimulations in control and NGF-
treated groups were determined in the three cell cultures. Results indicated that 
incubation with NGF had no effect on the Gs agonist-stimulated responses in mixed 
DRG cells, neuron-enriched cells and glial cells (p > 0.05, two-way ANOVA). This 
indicated that NGF failed to produce larger Gs agonist-stimulated responses in 
neuron-enriched cell preparations. 
Other than testing on Gs-agonist stimulated responses, the effect of NGF were also 
I 
tested on Gi/o-agonist-stimulated responses in isolated DRG cells. This was because 
in our preliminary experiments that was done some time ago, more than 20% 
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inhibition of the forskolin-stimulated adenylyl cyclase activity by A2-AR, 5HTIA and 
ji-OR receptor agonists (Gi/o agonists) had been observed in mixed DRG cells 
cultured after 5 days in the presence of NGF (unpublished data). However, this 
current study failed to show inhibition of the forskolin-stimulated responses by all 
Gi/o agonists after 2 days in culture in the absence of NGF. Therefore to mimic our 
preliminary studies, Gi/o agonist-stimulated responses on mixed DRG cells in the 
presence of NGF were assayed after 5 days (Fig. 5.15D-E). This preliminary result (n 
=1) showed that in the absence of NGF (50 ng/ml)，all Gi/o agonists tested could not 
inhibit the forskolin-stimulated responses after 5 days in mixed DRG cells. In the 
presence of NGF, the same was seen in majority of the Gj/o agonists except for 5-
HTia and a2-AR agonists. 8-OH-DPAT (1 |iM), inhibited the forskolin-stimulated 
responses by 76% while UK14304 (1 \iM) inhibited the basal activity by 42%. 
Besides, NGF has been shown to facilitated neurite outgrowth of adult DRG neurons 
(Lindsay, 1988). Therefore, mixed DRG cells, neuron-enriched cells and glial cells in 
the absence or present of NGF were fixed with acetone methanol (1:1) solution after 
2 days in cultures and stained with anti-TUJ-1 and anti-GFAP antibodies to identify 
DRG neurons and glial cells (Fig. 5.16). Preliminary results (n= 1) indicated that 
I 
incubation with NGF resulted in neurons with more extensive neurite outgrowth in 
neuron-containing cultures (Fig. 5.16 A-D). This observation was consistent with 
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previous findings (Lindsay, 1988). On the other hand, NGF has no effect on the 
expression of GFAP in glial cells (Fig. 5.16 E-F). 
5.4 Discussion 
Pharmacological evidence of functional expression of GPCRs is demonstrated by the 
receptor-specific agonist-stimulated responses being abolished by the receptor-
specific antagonist. In the first part of this study, the characterization of pain-related 
Gs-GPCRs on DRG cells reconfirmed the presence of EP4 and IP- receptors on both 
DRG neurons and glial cells. Besides, this study also revealed the functional 
expression of Pz-ARs and CGRP receptors, but not Pi-ARs, on DRG neurons and 
glial cells. Isoprenaline- and formoterol-stimulated responses in glial cells were 
smaller than those in mixed DRG cells. In contrast, consistent with cicaprost- and 
PGE2-stimulated responses, the CGRP-stimulated responses in glial cells were larger 
than those in the mixed DRG cells. 
The expression of p-ARs was reported in DRG neurons (Pluteanu et al., 2002) and 
was suspected in SGCs (Hanani, 2010) to mediate isoprenaline-stimulated responses. 
In this study, we clearly demonstrated that there is an increase of [^H]cAMP in 
neuron-enriched cells and glial cells upon incubation with isoprenaline, and the 
isoprenaline-stimulated response was blocked by the P2-AR antagonist, ICIl 18551. 
We provided the first evidence for isoprenaline-stimulated [^H]cAMP production in 
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DRG neurons and glial cells via activation of P2-ARS. It is suggested that after nerve 
injury, the DRG neurons become sensitive to catecholamines which are released by 
postganglionic neurons of the sympathetic division (Khanolkar et al., 1996), which 
leads to hyperalgesia (Ferreira, 1980; Khasar et al, 1999b). The expression of P2-
ARs in neurons and glial cells suggested that DRG cell cultures mimic neuropathic 
pain models. 
The isoprenaline- and formoterol-stimulated responses in mixed DRG cells were 
larger than those in the glial cells. This response pattern was different from the 
cicaprost- and PGEz-stimulated responses in mixed DRG cells and glial cells. It may 
suggest that the p2-AR responses of glial cells responses were not inhibited by the 
presence of DRG neurons. However, due to the larger responses of neuron-enriched 
cells, any inhibitory effect of neurons might be masked. Our preliminary data may 
provide evidence that neurons inhibit all Gs- and forskolin-stimulated responses of 
glial cells. 
CGRP stimulated the production of [^H]cAMP in both DRG neurons and glial cells. 
Although the presence of CGRP receptors has been shown in neurons in vivo and in 
vitro (Ceruti et al, 2011; Segond von Banchet et aL, 2002; Ye et al, 1999) and in 
glial cells in vitro (Ceruti et al., 2011), this is the first study to our knowledge that 
measured the CGRP-stimulated production of cAMP in glial cells. Although the 
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release of CGRP in the nerve ending is often linked to hyperalgesia, CGRP is also 
released by neuronal cell body to affect other neurons and their associated glial cells 
(Segond von Banchet et al.’ 2002). The expression of CGRP receptors on DRG 
neurons suggests the possibility that CGRP has a role in communication among 
neurons (Segond von Banchet et al, 2002) for the release of more CGRP (Thalakoti 
et al., 2007). The expression of CGRP receptors on glial cells revealed the possible 
involvement in pain processing in response to the release of CGRP by neurons. 
In our DRG cell cultures, neurons and glial cells were seeded at a density such that 
neuronal cell numbers in neuron-enriched and glial cell numbers in pure glial cell 
cuhures were similar to those in the mixed DRG cells on the day of assay. This 
allows for direct comparison among the three cell cultures. Comparing the CGRP-
stimulated responses in mixed DRG cells with those of glial cells, the responses in 
mixed DRG cell were smaller than in the pure glial cells. This inhibitory pattern was 
consistent with cicaprost- and PGE2-stimulated responses. It suggests that the CGRP-
stimulated responses of glial cells in the mixed DRG cell cultures were also inhibited 
by the presence of DRG neurons. However, to prove definitely whether DRG 
neurons inhibit the CGRP responses in glial cells will require individual labeling of 
< 
the glial cells, stimulating with CGRP and measuring the effect of CGRP-stimulated 
glial cell responses in the presence of DRG neurons. 
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Although the presence of CGRP receptors on neurons and glial cells was shown, the 
CGRP (1 |jM)-stimulated responses in the mixed DRG cells could not completely be 
antagonized by CGRPg-s? at 10 \iM. The log agonist concentration-response curves 
indicated that the responses at EC50 concentration of CGRP (40 nM) was completely 
inhibited by 10 |iM CGRP8-37. Nevertheless, the effect of CGRPg-s? on CGRP-
stimulated response was insurmountable, meaning that the effect of CGRPg.s? could 
not be overcome by increasing the concentration of CGRP. It is not likely that 
CGRP8-37 would act as a non-competitive antagonist, because CGRP8-37 reduced the 
binding of CGRP by competition with the same binding site as CGRP in a 
concentration-dependent manner (Segond von Banchet et al, 2002). It is 
controversial whether CGRPg-s? could completely antagonize the effect of CGRP. 
There are studies that showed CGRPg-s? acts as a competitive antagonist for CGRP 
receptors (Chiba et al., 1989; Doods et al., 2000), while some showed the failure of 
the blocking action by CGRPg-s? (Segond von Banchet et al, 2002; Xu et al.’ 1996). 
CGRP8-37 is currently the only antagonist for CGRP receptors that is commercially 
available; better CGRP antagonists are yet to be released commercially. 
The current study showed that CGRP-stimulated responses in glial cells, as well as 
< 
EP4- and IP-stimulated responses as previously identified (Ng et al.’ 2011), were 
inhibited by co-culture with neurons. This led to the investigation of the mode of 
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inhibition by neurons on glial cells. The possible modes of inhibition of glial cells by 
neurons can mediate directly through cell-cell contact or indirectly by the release of 
soluble factor(s). To test the modes of inhibition by neurons, we used transwell 
culturing system to assess the roles of cell-cell contact and the release of soluble 
factors on glial cell responses to cicaprost. In this study, neuron-enriched cells were 
cultured in the inserts and glial cells were cultured in the wells of transwell plates. 
When [^H]cAMP production was determined separately in neuron-enriched and glial 
cell cultures, the glial cells in such group (with access of soluble factors being 
released by neurons in the inserts) demonstrated smaller responses to cicaprost when 
compared with glial cell alone group (with no neurons in the inserts). This suggested 
that soluble factors released by neurons were involved in inhibiting glial cell 
responses. Besides, when neuron-enriched cells and glial cells were being cultured 
in the wells, responses to cicaprost were the smallest among all other groups. This 
suggested that cell-cell contact and soluble factors were important for inhibiting glial 
cells responses (manuscript in preparation). 
To account for the larger cicaprost-, PGE2-, and CGRP-stimulated [^H]cAMP 
productions in glial cells relative to neuron-enriched cells in dissociated cultures, it is 
worth investigating the expression of adenylyl cyclase isoforms in DRG cells. There 
is currently no report on the expression profile of adenylyl cyclase isoforms in DRG 
110 
cells. The use of adenylyl cyclase isoform-specific antibodies could be a solution to 
identify the isoforms, but it is currently unavailable. In pure glial cell cultures, RT_ 
PGR can be used to detect the mRNA expression of different adenylyl cyclase 
isoforms. However, this method cannot be used to detect the presence of adenylyl 
cyclase isoforms in neuron-enriched cells because this culture contains 
contaminating glial cells which interfere the results interpretation. 
The second part of the study was to characterize the presence of Gi/�-coupled class of 
GPCRs on neurons and glial cells. The presence of the Gi/�-coupled GPCR can be 
demonstrated when the Gi agonist inhibited the forskolin-stimulated responses and 
the Gi/o antagonist could restore the agonist-induced inhibition of the forskolin-
stimulated responses. The results failed to demonstrate the inhibition of forskolin-
stimulated responses by Gi/o agonists. Our previous unpublished data had shown 
significant inhibition of forskolin-stimulated responses in the mixed DRG cells after 
five days in culture in the presence of NGF (50 ng/ml). With reports showing that 
NGF facilitated the mRNA expression of (i-OR of DRG neurons after three days in 
culture (Franklin et al., 2009)，one would suspect that NGF would facilitate the 
expression of Gi/�-GPCRs. The presence of NGF showed no effect on the increase of 
I 
cicaprost-stimulated responses in mixed DRG cell cultures over five days (Wise, 
2006). However, the effect of NGF cannot be studied on neuron-enriched cells after 
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five days as glial cells in neuron-enriched cell cultures proliferate over time and 
decrease the purity of the neuron-enriched cell preparation. Studying this 
"contaminated" culture therefore becomes inadequate after three days. However, as 
demonstrated the lack of effect by NGF over five days on Gs-stimulated responses in 
the mixed DRG cells, it is also suspected that NGF will not produce significant effect 
on Gi/o-stimulated responses over time in cultures. 
Despite strong evidence showing the presence of pain-related Gj-coupled GPCRs on 
DRG cells, our system of measuring the inhibition of forskolin-stimulated [^H]cAMP 
production by Gi/o agonists produced inconclusive results. One potential problem for 
the measurement of inhibition of the forskolin-stimulated responses by a Gi/o agonist 
is that forskolin stimulated adenylyl cyclase activity for the production of [^H]cAMP 
in both neurons and glial cells in mixed DRG cell cultures, while the Gi/o-coupled 
GPCRs that mediate the inhibition of forskolin stimulation might not be expressed on 
neurons and/or glial cells. Therefore, it reduced the sensitivity of the measurement in 
mixed DRG cells and neuron-enriched cells. However, even in glial cell cultures that 
had over >99% glial cell purity, the inhibition of the forskolin-stimulated responses 
by a Gi/o agonist was still not prominent. Other methods are therefore needed to 
characterize the expression of Gi/�receptors on isolated DRG cells. 
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There are currently some other methods that are available and may be useful for the 
characterization of Gi/o-coupled GPCRs in cultures. Firstly, many Gi/o-GPCRs, such 
as opioid and CB receptors, are antigenic markers for the binding of specific 
antibodies (Ji et al.’ 1995; Ross et al, 2001). Detecting the presence of Gi/�-GPCR 
antibody immunoreactive cells will allow the characterization of Gi/�-GPCR on DRG 
neurons and glial cells. However, with the drawbacks as discussed in Chapter 4 for 
the use of antibodies in cultures, unless these antibodies produced very specific 
staining patterns with appropriate negative and positive controls of cells that are 
immunoreactive for the antibody, the evidence for the presence of GI/o-GPCR in 
DRG cell cultures is not persuasive with the use of immunocytochemical methods. 
The use of RT-PCR methods, on the other hand, to detect the presence of Gi/o-GPCR 
mRNA is relatively useful and the |x-OR receptor mRNA has been detected in mixed 
DRG cells (Franklin et al, 2009). The mRNA expression of Gi/o-GPCR can be 
characterized in glial cells because this cell preparation has over 99% purity of glial 
cells. The presence of a PGR product, the mRNA of the receptor, would provide 
evidence for the mRNA expression in glial cells. However, when the same procedure 
is performed in neuron-enriched cells, the use of PGR method has limitations 
because with around 70% purity of neurons, the cell type/s expressing the mRNA is 
unknown. 
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And, last but not least, measurement on the change of membrane potential upon 
activation of a Gi/�GPCR would be useful to characterize the presence of Guo-
GPCRs on neurons and glial cells. This method employs the use of the fluorescent 
bisoxonol membrane potential dye DiBAC. The fluorescence of the dye will be 
enhanced when the dye enters the cell membrane as a result of membrane 
depolarization. Measurement can be made on the change of fluorescence upon 
activation by the agonist of Gi/o-coupled GPCR. This method has been used to 
characterize the presence of opioid receptors on DRG neurons (Cunha et al, 2010) 
and should be used in the future to reveal the presence of other pain-related Gj/�-
receptors on DRG cells. 
5.5 Summary 
In this study, the presence of Gs-coupled GPCRs ( p 2 - A R s and CGRP receptors, but 
not Pi-ARs)，were identified in neurons and glial cells. Consistent with the EP4 and 
IP agonist-stimulated responses described previously (Ng et al.’ 2011), the CGRP-
stimulated responses in mixed DRG cells was smaller than those in the glial cells. 
This inhibitory pattern was not seen with P2-AR agonist stimulation. With all Gs-
GPCR agonist-stimulations, neuron-enriched cell preparations produced smaller 
responses than mixed DRG cells and glial cells. The addition of NGF did not lead to 
any increase in responses of neuron-enriched cells, but it facilitated neurite 
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outgrowth of DRG neurons. For the characterization of Gi/o-coupled GPCRs, agonist 
treatments failed to inhibit forskolin-stimulated responses in mixed DRG, neuron-
enriched cells and glial cells, which prevented the characterization of Gi/�-coupled 
GPCR expression. With strong evidence that the Gi/o-coupled GPCR being studied 
were expressed on DRG cells, other methods need to be identified in order to 
characterize the presence of these receptors in DRG neurons and glial cells. 
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Table 5.1 Summary of the drugs used to characterize GPCRs in isolated cultures of DRG cells 
GPCR Primary G-protein Agonist used Antagonist used 
coupling 
a2-AR Gi/o UK14304 (1 ^M) yohimbine (1 \M) 
Pi-AR GS isoprenaline (1 yM) S-(-)-atenolol (1 |JM) 
P2-AR Gs formoterol (1 ^M) ICI 118,551 (100 nM) 
C G R P Gs C G R P (1 mM) CGRP8-37 (10 _ ) 
CBl Gi/o R-(+)-methanandamide (100 nM) AM251 (10 pM) 
C B 2 GI/O L759656 (1 \ M ) A M 6 3 0 (10 PM) 
li-OR Gi/o DAMGO (1 \M) naloxone (1 ^M) 
ORLl Gi/o N/OFQ (1 ^M) 111397(300 nM) 
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Figure 5.2 CGRP receptor-mediated adenylyl cyclase activity in isolated DRG 
cells. Adenylyl cyclase activity was determined in mixed DRG cells, neuron-
enriched cells, and glial cells. Cells were incubated with control solution (basal) or 
with CGRP8.37 (10 \M) for 15 min before addition of CGRP (1 \M). Data are 
represented as means 士 SEM, from three independent experiments. *** p < 0.01, ** 
p < 0.001 compared with basal activity in the same cell group using one-way 
ANOVA. Np < 0.05, AAAp < 0.001 compared with the CGRP-stimulated responses 
in the same cell group using one-way ANOVA. <0.01’ # � p < 0.001 compared 
with the CGRP-stimulated responses in the mixed DRG cells using two-way 
ANOVA with Bonferroni's posthoc test. 
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Figure 5.3 CGRP-stimulated response patterns were similar to the cicaprost-
stimulated response patterns. Adenylyl cyclase activity was determined in mixed 
DRG cells, neuron-enriched cells, and glial cells. Cells were incubated with control 
solution (basal), IP receptor agonist (cicaprost, 40 nM) or CGRP receptor agonist 
(CGRP, 1 loM). Data are represented as means 士 SEM，from three independent 
experiments. # p <0.05, ## p < 0.01, ### p < 0.001 compared with the same 
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Figure 5.4 Log agonist concentration-response curve for CGRP in the presence 
of CGRP8-37 in mixed DRG cells. Adenylyl cyclase activity was determined in 
mixed DRG cells. Cells were incubated with control solution (basal) and CGRPg-s? 
(10 pM) for 15 mins before addition of increasing concentrations of the CGRP. Data 
are presented as means 士 SEM，from 3 independent experiments. * < 0.05，** < 
0.01 and < 0.001 compared with agonist alone at the same concentration using 
two-way ANOVA. Error bars smaller than the symbol size were not shown. 
120 
• basal 
• isoprenaline (1 \M) 
^ 1,5-1 • S-(-)-atenolol (1 ^M) 
o . . . • iso + a ten 
^ * * * 
T T 
o f f i l . O - I • ## 
5r CD = *** T 
n c I • ### S • 
g o • • *** 圓 • 
差10,1 nil! nlii nlil 
Mixed Neuron Glia 
Figure 5.5 Comparison of pi-AR-mediated adenylyl cyclase activity in isolated 
DRG cells. Adenylyl cyclase activity was determined in mixed DRG cells, neuron-
enriched cells and glial cells. Cells were incubated with control solution (basal) or S-
(-)-atenolol (1 |JM) for 15 min before addition of PI/P2-AR agonist, isoprenaline (1 
|JM). Data are represented as means 士 SEM，from four independent experiments. ** 
p < 0.01 and *** p < 0.001 compared with basal activity in the same cell group 
using one-way ANOVA. # # p < 0.01, ### p < 0.001 compared with the isoprenaline-
stimulated responses in the mixed DRG cells using two-way ANOVA with 
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Figure 5.6 Comparison of p2-AR-mediated adenylyl cyclase activity in isolated 
DRG cells. Adenylyl cyclase activity was determined in mixed DRG cells, neuron-
enriched cells, and glial cells. Cells were incubated with control solution (basal) or 
ICIl 18551 (100 nM) for 15 min before addition of P2-AR specific agonist, 
formoterol (1 jiM). Data are represented as means 土 SEM，from four independent 
experiments. < 0.001 compared with basal activity in the same cell group using 
one-way A N O V A . � ~ p < 0.001 compared with the formoterol-stimulated responses 
in the same cell group using one-way ANOVA. <0.01’ ### p < 0.001 compared 
with the isoprenaline-stimulated responses in mixed DRG cells using two-way 
ANOVA with Bonferroni's posthoc test. 
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Figure 5.7 Comparison of cicaprost-stimulated and p-AR agonist-stimulated 
adenylyl cyclase activities in isolated DRG cells. Adenylyl cyclase activity was 
determined in mixed DRG cells, neuron-enriched cells, and glial cells. Cells were 
incubated with control solution (basal), IP receptor agonist (cicaprost, 40 nM), non-
selective P1/P2-AR agonist (isoprenaline, 1 jiM) or P2-AR agonist (formoterol, 1 |JM). 
Data are represented as means 士 SEM，from four independent experiments. # p 
<0.05，##p < 0.01 compared with the same responses in mixed DRG cells using two-
way ANOVA with Bonferroni's posthoc test. 
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Figure 5.8 Characterization of the p-AR that mediated the isoprenaline-
stimulated responses. Adenylyl cyclase activity was determined in mixed DRG cells, 
neuron-enriched cells, and glial cells. Cells were incubated with control solution 
(basal), S-(-)-atenolol (1 ^M) or ICI118551 (100 nM) for 15 min before the addition 
of non-specific P-AR agonist, isoprenaline (1 |JM). Data are represented as means 士 
SEM, from four independent experiments. * p< 0.05，** p < 0.01 and *** p < 0.001 
compared with basal activity in the same cell group using one-way ANOVA. ^ p < 
0.01 and p < 0.001 compared with the isoprenaline-stimulated responses in the 
same cell group using one-way ANOVA. ## p < 0.01 compared with the 
isoprenaline-stimulated responses in the mixed DRG cells using two-way ANOVA 
with Bonferroni's posthoc test. 
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Figure 5.9 Characterization of the az-AR-mediated adenylyl cyclase activity in 
isolated DRG cells. Adenylyl cyclase activity was determined in mixed DRG cells, 
neuron-enriched cells, and glial cells. Cells were incubated with control solution 
(basal) or a2-AR specific antagonist, yohimbine (1 |iM) for 15 min before addition of 
a2-AR specific agonist, UK14304 (1 pM) alone or forskolin and UK14304. Data are 
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Figure 5.10 Characterization of the CBl receptor-mediated adenylyl cyclase 
activity in isolated DRG cells. Adenylyl cyclase activity was determined in mixed 
DRG cells, neuron-enriched cells and glial cells. Cells were incubated with control 
solution (basal), or CBl specific antagonist, AM251 (10 |JM) for 15 min before 
addition of CBl specific agonist, R-(+)-methanandainide (100 nM) alone or 
forskolin and R-(+)-methanandamide. Data are represented as means 士 SEM, from 
three independent experiments. 
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Figure 5.11 Characterization of the CB2 receptor-mediated adenylyl cyclase 
activity in isolated DRG cells. Adenylyl cyclase activity was determined in mixed 
DRG cells, neuron-enriched cells, and glial cells. Cells were incubated with control 
solution (basal) or CB2 specific antagonist, AM630 (10 [iM) for 15 min before 
addition of CB2 agonist, L79656 (1 ^M) alone or forskolin and AM630. Data are 
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Figure 5.12 Characterization of the 5-HT lA receptor-mediated adenylyl cyclase 
activity in isolated DRG cells. Adenylyl cyclase activity was determined in mixed 
DRG cells, neuron-enriched cells and glial cells. Cells were incubated with control 
solution (basal) or 5-HTIA receptor antagonist, S-WAYI00135 (500 nM) for 15 min 
before addition of 5-HT lA receptor agonist, 8-0H-DPAT (1 ~) alone or forskolin 
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Figure 5.13 Characterization of the ji-OR receptor-mediated adenylyl cyclase 
activity in isolated DRG cells. Adenylyl cyclase activity was determined in mixed 
DRG cells, neuron-enriched cells, and glial cells. Cells were incubated with control 
solution (basal) or |i-OR receptor antagonist, naloxone (1 (oM) for 15 min before 
addition of |a-OR receptor specific agonist, DAMGO (1 ^M) alone or forskolin and 
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Figure 5.14 Characterization of the ORLl receptor-mediated adenylyl cyclase 
activity in isolated DRG cells. Adenylyl cyclase activity was determined in mixed 
DRG cells, neuron-enriched cells, and glial cells. Cells were incubated with control 
solution (basal) or ORLl specific antagonist, J11397 (300 nM) for 15 min before 
addition of ORLl receptor agonist, N/OFQ (1 i^M) alone or forskolin and N/OFQ. 
Data are represented as means 士 SEM，from three independent experiments. 
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Fig. 5.16 Effect of NGF on phenotypic properties of DRG cells. 
Immunofluorescence images showing representative fields of (A-B) mixed DRG 
cells and (C-D) neuron-enriched and (E-F) glial cells pretreated with (A,C,E) control 
solution and (B,D,F) NGF on day 2. Neurons were identified with anti-TUJ-1 
antibodies (1:1000, green), glial cells were identified with anti-GFAP antibodies 
(1:500, red) and cell nuclei were stained with Hoechst 33342 stain (blue). Scale bar 
represents 25 |Lim. 
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Chapter 6 
Conclusion and further studies 
In conclusion, this thesis has presented evidence that isolated DRG cell cultures may 
represent cells with neuropathic pain properties. Using immunocytochemical 
methods, we identified glial cell proliferation and an increase in GFAP fluorescence 
intensity in isolated DRG cell cultures. Proliferation of glial cells and increase in 
GFAP expression are characteristics of glial cell activation after nerve injury. These 
characteristics of glial cells are likely to contribute to the maintenance of neuropathic 
pain. Using pharmacological methods, the presence of P2-ARS and CGRP receptors 
were identified in both neurons and glial cells in addition to EP4 and IP receptors. 
Similar to EP4 and IP receptor agonist-stimulated responses, glial cell responses to 
CGRP were inhibited by co-culture with neurons. This study also revealed a novel 
neuron-glia interaction that neurons inhibited the adenylyl cyclase responses of glial 
cells to agonist stimulation. 
Further studies are required to determine the functions for the expression of pain-
related receptors on glial cells and the functions and mechanisms of how neurons 
inhibited glial cell adenylyl cyclase activity. Our on-going investigations have 
suggested that both neuron-glial cell contact and neuron-derived soluble factor(s) are 
involved. As we could not identify the proportion of different types of glial cells in 
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isolated DRG cell cultures, we are currently unable to suggest the type(s) of glial 
cells that neurons are likely to inhibit. 
The use of isolated DRG cell cultures is useful by allowing studies on separated 
DRG cells to reveal possible neuron-glia interactions. However, currently, pure 
neuronal cell cultures cannot be obtained due to proliferation of the "contaminating" 
glial cells. In order to be sure that the agonist-stimulated responses in neuron-
enriched cultures come from neurons but not the contaminating glial cells, 
embryonic DRG, which consists of neurons but nearly no glial cells, can be isolated 
and studied (Hall, 2006). 
In in vivo condition, DRG neurons and SGCs are in close association with each other, 
forming a unique functional complex. This physical relationship was however 
interrupted during the process of cell preparation to give dissociated cell cultures. In 
the future study of DRG cells in cultures, the physical relationship between neurons 
and glial cells will need to be carefully studied. Besides, one should not presume a 
similar cellular distribution of proteins such as receptors, transporters and enzymes in 
in vitro condition based on in vivo study data. 
( 
In conclusion, this thesis suggested that DRG glial cells are clearly not passive 
bystanders but are actively responding to neuron injury as in isolated DRG cell 
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cultures. Besides, we showed that neuron-glia interactions played a role in 
modulating responses of neurons and glial cells. With considerable interest in 
studying neuron-glia interactions and the use of dissociated cultures of DRG and TG 
cells, the roles played by glial cells, which are capable of sensing nerve injury and 
expressing pain-related receptors, should be carefully considered. In the future, glial 
cells are likely to be the targets for the treatment of neuropathic pain by controlling 
their activation and the communication with neurons. 
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